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ABSTRACT 
Acute myeloid leukemia (AML) is a type of blood cancer, characterized by clonal expansion 
and loss of differentiation ability of myeloid progenitor cells leading to abnormal 
accumulation of immature myeloid cells (myeloblasts) in the bone marrow and peripheral 
blood. 
This thesis (study I to IV) focused on the identification and characterization of genes which 
are required for AML growth. The final study (study V) aimed to uncover the role of NAP1L3 
in normal hematopoietic stem cells (HSCs). 
In studies I and II, we performed large-scale RNA interference screens in mouse and AML 
human cell lines to identify novel factors and pathways required for AML growth. Using this 
approach, we identified two novel targets: Chromatin remodeling factor CHD4 (study I) and 
the transcription factor GTF2IRD1 (study II), which display both a strong inhibitory effect 
on the growth of AML cells and a less negative effect on normal hematopoietic cells. 
Using RNA interference and CRISPR-Cas9 techniques, we revealed that these genes were 
crucial for AML cell growth in vitro and in vivo. Knockdown of either CHD4 or GTF2IRD1 
accumulated cells in the G0 phase of the cell cycle and resulted in downregulation of MYC 
and its target genes. We demonstrated the inhibitory role of CHD4 knockdown on the growth 
and maintenance of primary childhood AML in an ex vivo setting, as well as in a xenograft 
model by transplanting patient-derived samples into humanized NSG-SGM3 mice. 
GTF2IRD1 knockdown reduced the number of primary childhood and adult AML cells in ex 
vivo culture and delayed AML progression in the transplanted animal model. Therefore, 
CHD4 and GTF2IRD1 are important for AML cell growth, and interestingly the knockdown 
of these two genes did not show a strong inhibitory effect on normal hematopoietic cell 
growth. 
In study III, we described the role of an epigenetic enzyme, the histone methyl-transferase 
EHMT1 in AML. We used RNA interference, CRISPR-Cas9, and pharmacological 
approaches to inhibit EHMT1 expression, which prevented the growth of various AML cell 
lines and primary AML patient samples. Knockdown of EHMT1 significantly delayed 
disease progression in AML mouse models and prolonged their survival. Next, we employed 
CRISPR-Cas9 technology to generate single and double gene knockouts of EHMT1 and its 
homolog EHMT2, which showed that both enzymes cooperatively play a role in AML cell 
proliferation and shared a similar cellular mechanism as individual knockouts of either gene 
resulted in an increased number of cells in G0 phase of the cell cycle. RNA sequencing of 
the transcriptome of AML cells with EHMT1 and EHMT2 knockdown identified several 
common biological processes, including cell differentiation, proliferation and survival, as 
well as other unshared pathways and downstream effectors. 
In study IV, we contributed to Nikolas Herold’s study, who found that deoxynucleoside 
triphosphate (dNTP) triphosphohydrolase SAM domain and HD domain 1 (SAMHD1) plays 
a role in detoxifying intracellular ara-CTP in cells treated with the deoxycytidine analog 
cytarabine (ara-C). Transient reduction of SAMHD1 expression by using the simian 
immunodeficiency virus (SIV) protein Vpx significantly increased the sensitivity of AML 
cells to ara-C, whereas AML cells lacking SAMHD1 transplanted into recipient mice were 
hypersensitive to ara-C. We showed that in vitro treatment of primary AML patient samples 
with Vpx, which suppresses SAMHD1, resulted in reduced proliferation of AML but not 
normal cells. Together, our data suggest that SAMHD1 inhibition can be used as a therapeutic 
strategy for cancer (AML) patients with high SAMHD1 expression.  
In study V, our aim was to identify novel epigenetic regulators of normal HSCs. We found 
high expression level of Nap1l3, a member of nucleosome assembly proteins (NAPs), as a 
histone chaperone in HSCs. Loss of function of mouse Nap1l3 mediated by shRNA or 
CRISPR-Cas9 impaired the maintenance and differentiation of HSCs in both our in vitro and 
in vivo studies. Moreover, downregulation of NAP1L3 in human UCB HSCs significantly 
decreased both the number of colonies formed by HSCs and their proliferation in vitro due 
to cell cycle arrest in the G0 phase. Xenograft mouse models using human HSCs with 
NAP1L3 knockdown showed a reduction of HSC reconstitution and bias in differentiation. 
Furthermore, we observed upregulation of several HOX genes (HOXA3, HOXA5, HOXA6 
and HOXA9) under NAP1L3 suppression in human HSCs. 
Altogether, in this thesis, we showed the important roles of CHD4, EHMT1 and GTF2IRD1 
in AML cell expansion, identifying them as potential novel targets for AML treatment. 
Moreover, we revealed the cellular mechanisms and RNA expression patterns under 
knockdown of these genes. We contributed to the study that found SAMHD1 expression level 
can be used as a prognostic marker for ara-C treatment and that inhibition of SAMHD1 
increases the sensitivity of AML cells to ara-C treatment. Finally, we identified a novel 
regulatory role for NAP1L3 as a histone chaperone in self-renewal and differentiation of 
HSCs. 
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1 INTRODUCTION 
1.1 HEMATOPOIETIC SYSTEM 
The hematopoietic system includes the bone marrow (BM), spleen, lymph nodes and thymus, 
which are involved in the production of various blood cell types within the body. Specialized 
blood cells perform different functions in the body including oxygen supply, contributing to 
wound healing and protection from pathogens.  
Oxygen is a vital component of all human cells, essential for cell growth and energy 
production. Red blood cells (RBCs) are responsible for oxygen transfer from the lung to all 
cells in the human body. Oxygen transport from the lung to the blood and uptake by cells is 
performed by passive diffusion (Krogh 1919). The protein hemoglobin in RBCs facilitates 
the transferring of 98% of oxygen in blood via reversible binding, whilst the rest of oxygen 
is found in free form in plasma and inside erythrocytes (Popel 1989). 
Blood cells play an important role during hemostasis to stop bleeding, induce inflammation 
and prevent infection. In the wound healing process, numerous types of blood cells including 
platelets, neutrophils, monocytes, lymphocytes and dendritic cells are involved. The wound 
repair process is divided into three stages: inflammation, new tissue formation and 
remodeling (Gurtner, Werner et al. 2008). In the first stage, blood cells (immune cells and 
platelets) activate the coagulation cascade (hemostasis), inflammation pathways and prime 
anti-infection machinery. Platelets aggregate at the wound site and induce plug formation, 
after which insoluble fibrin forms a mesh to strengthen and stabilize the blood clot (Gale 
2011).  
Blood cells also contribute to both types of immunity, the innate and adaptive responses. The 
major blood cells and their products in the innate immune system include monocytes, 
macrophages, neutrophils and natural killer (NK) cells. The central players in the innate 
immune system are neutrophils, which are recruited and activated at the site of infection to 
eliminate pathogens (Witko-Sarsat, Rieu et al. 2000). NK cells are morphologically similar 
to B and T lymphocytes, but unlike lymphocytes they do not have specific antigen receptors. 
NK cells recognize abnormal cells through either FcR (immunoglobin receptors) or their 
receptors for MHC (major histocompatibility complex) class I (Parkin and Cohen 2001). The 
adaptive immune system consists of two major types of lymphocytes: T cell are involved in 
cell-mediated response and B cells are mainly responsible for antibodies-related (humoral) 
immunity. 
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1.1.1 Hematopoiesis 
Hematopoiesis describes the procedure of formation, development and differentiation of 
blood cells. In a healthy adult human, the blood system continuously produces approximately 
1011-1012 blood cells daily (Beerman, Maloney et al. 2010, Doulatov, Notta et al. 2012, 
Harrison 1979). Here, the term of blood cells includes RBCs, platelets and white blood cells 
WBCs). The main hematopoietic cell types and their functions are summarized in Table 1. 
The most common cells found in blood are RBCs, also named erythrocytes. In the human 
body, 2-3×106 RBCs are produced every second in the BM with a life span of 120 days. 
Macrophages in the spleen or liver remove old or damaged RBCs from the blood circulation. 
Platelets originating from megakaryocytes play a role in hemostasis, thrombosis, 
inflammation and the immune system with an average life time of 8-10 days (Ho-Tin-Noe 
2018). 
WBCs are divided into two major subgroups: lymphoid and myeloid cells. The lymphoid 
cells consist of T cells, B cells and NK cells, which have roles in innate and adaptive 
immunity. The myeloid group includes monocytes, granulocytes (neutrophils, eosinophils 
and basophils), megakaryocytes and erythrocytes. 
In mammalian adults, all blood cell types originate from a rare cell type in the BM termed 
hematopoietic stem cells (HSCs). 
 
Table1. Hematopoietic cell types and their function. 
Progenitors Subtype Function 
Myeloid 
cells 
Eosinophils Involved in hypersensitivity and helminth infection 
Granulocytes 
(neutrophils) Ingestion and destruction of microorganism 
Basophil Inflammatory reactions and acute and chronic allergic development  
Macrophages Derived from monocytes, respond to foreign material and release substances to stimulate other immune cells  
Megakaryocytes Give rise to platelets  
Monocytes Circulate in blood and migrate to tissue, they differentiate into macrophages  
Erythrocytes  Oxygen delivering 
Mast cells  Involved in allergy, anaphylaxis, wound healing, angiogenesis 
Lymphoid 
cells 
Cytotoxic T cells Eradicate virus-infected cells as well as tumor cells  
T helper (TH) cells Produce cytokines to activate B cells and T cells  
Memory T cells  Previously encountered and respond to their cognate antigen and ready to respond faster and stronger to the same antigen   
B cells Produce antibodies  
Dendritic cells  Process antigen and present to T cells  
Natural killer cells Part of innate immune system to kill viral infected cells and cancer cells 
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1.1.2 Hematopoietic stem cells and differentiation  
HSCs are characterized by a self-renewal capacity to generate more stem cells (clonal 
expansion) and their ability to differentiate into various kinds of progenitor cells (clonal 
extinction) (Pina and Enver 2007). Indeed, HSCs represent the top cellular hierarchy of blood 
cells, from which progenitors derive, that give rise to common precursor cells (Figure 1). 
Studies have shown that only approximately 1000 HSCs contribute to hematopoiesis and 
peripheral blood production (Catlin, Busque et al. 2011). Early in vivo HSC tracing 
experiments performed in mice, revealed that the average cell division time of a quiescent 
HSC is 57 days (Cheshier, Morrison et al. 1999). Interestingly, other studies showed that 
dormant HSCs divided every 145 days or five times in a mouse’s lifespan (Wilson, Laurenti 
et al. 2008). Dormant HSCs (d-HSCs) are thought to only serve in injury situations.  
 
 
Figure 1. Hierarchy model of hematopoiesis. Hematopoietic stem cells (HSCs) with self-renewal 
capacity differentiate into progenitor cells and all mature blood cells. Figure reprinted with permission 
from the publisher (Wikipedia 2018). 
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In humans, it is not feasible to estimate the division time of HSCs by BrdUrd or H2-B 
labelling, but by using telomere length or the changing ratio of maternal/parental X-
chromosome with age, the HSC replication rate was estimated to be on average once every 
40-45 weeks (Catlin, Busque et al. 2011, Shepherd, Guttorp et al. 2004). However, 
considering mouse and human lifespans, the division number of HSCs is roughly similar 
between mice and humans.  
 
Origin of HSCs  
During embryogenesis, blood cells originate from the mesodermal layer. The first wave of 
blood cell development occurs in the yolk sac (day E7.5 in mouse) and is termed “primitive” 
or embryogenic hematopoiesis, as it produces primitive nucleated erythroid, macrophage and 
megakaryocytes progenitors (Figure 2) (Palis, Robertson et al. 1999, Tober, Koniski et al. 
2007). The second hematopoietic wave in the yolk sac, embryo proper and allantois generates 
erythroid and myeloid progenitors (EMP); B-1a and T lymphocytes (Dzierzak and Bigas 
2018). Thus, the formation of blood cells in the first and second wave occurs without existing 
of HSCs. In the mouse embryo, HSCs originate at day E9.5 from endothelial cells expressing 
vascular endothelial cadherin (Zovein, Hofmann et al. 2008).  
 
Figure 2. Development of 
hematopoiesis in mice. 
A. The position of 
hematopoiesis first in yolk sac 
(YS) blood island then in 
aorta-gonad mesonephros 
(AGM) at day 10.5 and later in 
fetal liver, spleen and BM. B. 
The blood lineage hierarchy in 
each step of hematopoiesis. 
ECs (endothelial cells), RBCs 
(red blood cells), LTHSC 
(long-term hematopoietic 
stem cell), ST-HSC (short-
termhematopoietic stemcell), 
CMP (common myeloid 
progenitor), CLP (common 
lymphoid progenitor), MEP 
(megakaryocyte-erythroid 
progenitor), GMP 
(granulocyte-monocyte 
progenitor). C. time frame and 
location of hematopoiesis. Figure reprinted with permission from the publisher (Orkin and Zon 2008). 
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Hematopoiesis converts to “definitive” in aorta-gonad mesonephros (AGM), fetal liver and 
eventually in the BM (adult hematopoiesis) (Dzierzak and Medvinsky 1995, Galloway and 
Zon 2003). 
 
HSC Heterogeneity  
For a long time, HSCs were thought to be one homogenous population which gave rise to 
multipotent progenitors (MPPs) which in turn differentiated into different lineages. However, 
recent findings demonstrate that HSCs are heterogonous. Indeed, single-cell transplantation 
of HSCs showed a broad range of variability in the reconstitution and self-renewal capacity 
of mouse HSCs (Dykstra, Kent et al. 2007, Morita, Ema et al. 2010, Yamamoto, Morita et al. 
2013). Taking advantage of new in vivo imaging technology, HSCs are now classified as 
having long-, intermediate- and short-term self-renewal capacities based on their specific cell 
surface markers (Doulatov, Notta et al. 2012, Notta, Doulatov et al. 2011). Aside from their 
heterogeneity in self-renewal capacity, single-cell transplantation experiments also 
demonstrated that the majority of HSCs are biased towards certain lineages during 
differentiation and only a few can differentiate equivalently to produce all mature blood cells 
(Carrelha, Meng et al. 2018, Dykstra, Kent et al. 2007, Morita, Ema et al. 2010, Yamamoto, 
Morita et al. 2013). Additionally, single-cell RNA sequencing revealed the heterogeneity of 
RNA expression profiles amongst HSCs, which reflect their ultimate destination of 
differentiation (Adolfsson, Mansson et al. 2005, Velten, Haas et al. 2017). Thus, all current 
data suggest that transcriptional lineage programming determines HSC function and is 
associated with HSC lineage commitment.  
Together, considering the limitations to isolate pure HSCs and using different definition and 
markers to identify HSCs in studies, HSCs are a heterogeneous population with varying RNA 
expression profiles, differing differentiation abilities and distinct reconstitution and self-
renewal capacities.   
 
Isolation of hematopoietic stem cells 
As discussed above, HSCs are very rare, which makes their deep characterization difficult. 
For example, in human BM, where the HSCs reside, only 1 in a million cells represents a 
HSC (Wang, Doedens et al. 1997). So far, no unique marker for HSCs has been discovered.  
For practical reasons, HSCs have mainly been studied in the mouse. To immune phenotypic 
isolation of mouse HSCs from the BM, HSCs were first defined as Lin-cKit+Sca-1+ (LSK) 
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cells in 1992 (Ikuta and Weissman 1992). Among the LSK cells, functional studies revealed 
that the CD34- population was significantly enriched for long-term HSCs (Osawa, Hanada et 
al. 1996). Later, the HSCs could be further enriched to constitute 35-50% of the isolated cells, 
using an alternative sorting protocol defined as the SLAM phenotype (CD150+CD48-) (Kiel, 
Yilmaz et al. 2005).  
To isolate and study HSCs in humans, The surface marker CD34 was suggested to enrich 
HSCs as it is found on less than 5% of all blood cells (Civin, Strauss et al. 1984). Although 
more than 99% of all human HSCs are CD34+, several studies have shown the existence of 
CD34- HSCs (Ishii, Matsuoka et al. 2011). Further studies have shown that HSCs in humans 
can be further enriched in cells not expressing CD38 or CD45RA (Bhatia, Wang et al. 1997, 
Lansdorp, Sutherland et al. 1990). Another interesting marker is CD90 (Thy1) which has 
been used to obtain highly purified HSCs (Baum, Weissman et al. 1992). Therefore, Lin-
CD34+CD38-CD90+CD45RA- is an immune phenotype that has been widely used to study 
and isolate human HSCs in the field, although this protocol is continuously being updated 
with additional markers. For example, including CD49f marker in Lin-CD34+CD38-
CD90+CD45RA- cells led to further purification of long-term repopulating HSCs (Notta, 
Doulatov et al. 2011). Although the research field has not been able to isolate a completely 
pure population of HSCs, which might reflect their heterogeneity, we can now enrich them 
for further study of HSCs. A summary of specific markers used for isolation of each HSC 
and progenitor population in mouse and human is depicted in Figure 3.  
 
Bone marrow niche 
The concept of a niche for hematopoietic stem cells was first suggested in 1978 (Schofield 
1978). This hypothesis proposed that HSCs associated with other cells in BM. BM is a semi-
solid tissue located in the spongy or cancellous portions of the tibia, femur, ribs, sternum, 
vertebrae and pelvis. The BM niche regulates various HSC activities including self-renewal, 
differentiation, mobilization, and engraftment. The main cell types in the BM niche are 
osteolineage cells, perivascular cells, endothelial cells, adipocytes, macrophages and 
mesenchymal stem cells (MSCs) (Figure 4). 
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Figure 3. Cell surface markers of main classes of stem cells and progenitors in mouse and 
human. Figure reprinted with permission from the publisher (Doulatov et al. 2012). 
 
It has previously been reported that various types of osteolineage cells reside in the BM with 
distinct roles regulating different lymphoid cells. Knockout of osteocalcin (Ocn)-expressing 
osteolineage cells results in a loss of T cells (Yu, Saez et al. 2015), whereas osterix-
expressing (Osx+) and Col(I)a2.3-expressing osteolineage cell deletion impairs the 
maturation of B cell progenitors (Visnjic, Kalajzic et al. 2004, Zhu, Garrett et al. 2007). Many 
HSCs localize adjacent to the blood vessels, which suggests that the perivascular region is 
crucial for HSC maintenance. In addition, MSCs also reside near vessels and can differentiate 
into osteolineage cells, chondrocytes, and adipocytes. Genetic deletion of MSCs in mice has 
recently been shown to affect the HSCs (Mendez-Ferrer, Battista et al. 2010), for example 
SIPA-1 deletion leads to the development of myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN) phenotype in mice (Xiao, Dolinska et al. 2018). Another cell type which 
surrounds sinusoidal endothelial cells, or is located near to the endosteum, is CXC chemokine 
ligand (CXCL)12-abundant reticular (CAR) cells which co-localize with HSCs (Sugiyama, 
 8 
Kohara et al. 2006). Ablation of CAR cells dramatically affects adipogenic and osteogenic 
differentiation, whilst decreased production of stem cell factor (SCF) and CXCL12 
cytokines, subsequently caused a reduction in erythroid progenitors, cycling lymphoid cells 
and HSCs (Omatsu, Sugiyama et al. 2010).  
Endothelial cells secrete specific growth factors in a paracrine-specific manner, known as 
angiocrine factors, and balance self-renewal and support expansion of hematopoietic stem 
and progenitor cells (HSPCs) over differentiation (Kobayashi, Butler et al. 2010). Moreover, 
they express adhesion molecules including P-selectin, E-selectin, vascular cell adhesion 
molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (Mazo, Gutierrez-Ramos et al. 
1998, Rafii, Mohle et al. 1997) which are important for HSCs homing into the BM. The 
percentage of adipocytes in the BM or fatty marrow increases with age in both humans and 
mice, yet HSC function decreases, implying that adipocytes negatively regulate HSCs (Yu 
and Scadden 2016). 
 
 
 
Figure 4. HSC niche in the adult bone marrow. Schematic of various stromal cells types and 
extrinsic signals including growth factors, cytokines, morphogens, extracellular matrix proteins, and 
adhesion molecules in the adult BM that contribute to the maintenance and regulation of HSCs. Figure 
reprinted with permission from the publisher (Yu and Scadden 2016).  
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Macrophages are another key cell type in the BM niche. Depletion of macrophages caused 
loss of osteoblasts, significant reduction of HSC-trophic cytokines and HSC mobilization 
into the blood (Winkler, Sims et al. 2010). Interestingly, macrophages supported erythroid 
lineage development (Palis 2016).  
New findings have suggested that HSCs reside in different spots within the BM and 
depending on their location may have different functions. For example, some studies have 
shown that osteoblastic cells regulate HSCs via N-cadherin (Calvi, Adams et al. 2003, Zhang, 
Niu et al. 2003). Yoshihara suggested HSCs close to thrombopoietin-producing osteoblasts 
remain in a quiescent state (Yoshihara, Arai et al. 2007), whilst another study revealed that 
the vascular cells regulate HSCs migration to the vascular niche via CXCL12 (Kiel and 
Morrison 2006). Altogether, it seems that HSC localize to a specific area within the BM and 
are surrounded by hematopoietic as well as non-hematopoietic cells, which in turn provide a 
tonic regulation of HSCs. Therefore, any perturbation of these non-hematopoietic cells may 
cause abnormal function of HSCs.   
 
1.1.3 Epigenetic regulation of hematopoiesis  
The term “epigenetic” (Epi is Greek prefix means “over”, “outside of”) was suggested by 
Conrad Waddington in 1942 (Waddington 2012). Epigenetics refers to the stable and 
heritable modifications in gene activity that occur without any alteration in DNA sequence, 
including histone modification, DNA methylation and non-coding RNAs. Epigenetic 
regulation is a complex process by combination and interaction of many epigenetic modifiers 
which add “writers” or remove “erasers” modifications on histones or DNA and recognize 
and respond to the modifications “readers”.  
In eukaryotes DNA is wrapped around a histone octamer called the nucleosome and 
nucleosome units fold into chromatin structure. Epigenetic regulatory factors modify 
chromatin structure in both a global and gene-specific manner by post-translational 
modification of histones and/or DNA methylation to provide or prevent access of 
transcription factors (TFs) to promoter regions. In other words, epigenetic modifications can 
result in either “loose” chromatin regions, called euchromatin, which are available for TFs 
or “tightly” packed chromatin regions, termed heterochromatin, which are inaccessible for 
transcription. For example, transcriptionally silenced regions in eukaryotic cells are 
associated with methylation of DNA in CpG regions and histone H3 dimethylated on lysine 
9 (H3K9me2) and histone H3 trimethylated on lysine 27 (H3K27me3) whereas 
transcriptionally active regions contain high levels of H4 trimethylated on lysine 4 
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(H3K4me3) and lack DNA methylation (Li, Carey et al. 2007). Transcription of a gene occurs 
on naked DNA by TFs and RNA polymerase enzymes. Therefore, epigenetic mechanisms to 
alter chromatin and provide naked DNA for co-activators and TFs is the key step to determine 
cell identities.  
The epigenetic landscape was first suggested by Waddington in 1957 to explain the role of 
epigenetic factors to canalize cells, originating from stem cells, during differentiation (Ferrell 
2012). Therefore, epigenetic factors stabilize gene expression profile in cells and canalize 
cell-type identities. Transcription and epigenetic regulatory factors play crucial roles in 
keeping the balance between HSC maintenance and differentiation. However, differentiation 
in the hematopoietic system is not as simple as Waddington’s original theory. First, in the 
beginning of hematopoiesis (the first and second wave) in the embryo stage, differentiated 
cells are made prior to and independently of HSCs. Furthermore, it was confirmed that by 
inducing expression of specific lineage TFs in hematopoietic cells, it is possible to switch the 
cells from one lineage to another (Graf 2002). Below, we will discuss the important 
epigenetic factors which play a role in hematopoiesis.  
 
DNA methylation 
DNA methylation was first suggested in 1975 as an epigenetic mechanism of imprinting to 
inactivate the X-chromosome in female cells (Holliday and Pugh 1975, Riggs 1975). In 
human cells, DNA methylation predominantly occurs in cytosine at the C5 position. DNA 
methylation mainly occurs in CpG dinucleotides (60-80% of all CpGs are methylated) at the 
promoter regions which influences transcriptional activity (Lister, Pelizzola et al. 2009, 
Saxonov, Berg et al. 2006). 
Stem cell differentiation is linked to gradual methylation of CpG islands by DNA 
methyltransferases (Trowbridge and Orkin 2011). In hematopoiesis, different methylation 
patterns are significantly correlated with the global gene expression pattern and results in cell 
fate decisions (Ji, Ehrlich et al. 2010). DNA methylation might play a role as an epigenetic 
gatekeeper to retain a specific-cell lineage pattern during differentiation.  
Two methyltransferases in particular, DNMT3a and DNMT3b are required for de novo 
methylation. During differentiation of HSCs, DNMT3a and DNMT3b are involved in the 
silencing of genes which regulate HSC self-renewal activity (Trowbridge and Orkin 2011). 
Hence, deletion of DNMT3a and DNMT3b in HSCs caused upregulation of self-renewal 
genes and subsequently increased HSC self-renewal and impaired HSC differentiation 
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(Challen, Sun et al. 2014). Another methyltransferase, DNMT1 preserves the DNA 
methylation patterns during DNA replication. DNMT1 also has an important role during HSC 
differentiation towards multipotent progenitors of a myeloid-restricted lineage (Trowbridge, 
Snow et al. 2009). Genes that are important in maintaining HSCs, including Meis1, Hoxa9 
and Prdm16, are heavily methylated and so transcriptionally silenced in progenitor cells 
during differentiation (Kosan and Godmann 2016). Whereas, active genes in differentiated 
cells are found to be methylated in HSCs and selectively become demethylated during the 
lineage commitment process. For example, Gadd45a a critical gene in myeloid development 
was found to be upregulated and demethylated in cells transitioning from common myeloid 
progenitor (CMP) to granulocyte-monocyte progenitor (GMP) stage whereas it is methylated 
and silenced in HSCs (Ji, Ehrlich et al. 2010).  
 
Histone modifications  
There are many post-translational histone modifications which influence chromatin structure 
including acetylation, methylation, phosphorylation, ubiquitinylation, sumoylation, 
adenosine diphosphate (ADP) ribosylation, and deamination (Kouzarides 2007). These 
modifications are associated with various processes including transcription regulation, DNA 
repair, DNA replication and condensation (Kouzarides 2007). Histone-modifying enzymes 
are summarized in Table 2. 
There are some important histone-modifying enzymes in hematopoiesis which play key roles 
in HSC function including self-renewal and differentiation. Important histone 
acetyltransferase (HAT) that transfer acetyl groups to specific lysine residue of histones in 
hematopoiesis are p300/CBP (CBP and p300), MYST (Tip60, MOZ, MORF, HBO1 and 
HMOF), and GNAT (PCAF, Gnc5 and ELP3) (Sun, Man et al. 2015). P300 is associated 
with promoting differentiation of HSCs by acetylation of the C-Myb promoter region, 
whereas CBP acetylates Gfi1b and promotes self-renewing of HSCs and blocks 
differentiation (Sun, Man et al. 2015).  
Polycomb-group (PcG) proteins are histone modifiers which exist in two main complexes; 
polycomb repressive complex 1 (PRC1) and 2 (PRC2). They have been shown to be involved 
in gene repression in HSCs during self-renewal and differentiation (Radulovic, de Haan et 
al. 2013).  
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Table 2. Histone-modifying enzymes. Table adapted with permission from the publisher 
(Kouzarides 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRC2 includes the enhancer of zeste (E(z)), Suppressor of zeste 12 (Suz12) and Extra sex 
combs (Esc). Overall, PRC2 is responsible for the methylation of H3K27 (H3K27me2 and 
H3K27me3) at the promoter sites which is associated with transcriptional repression of target 
genes. PRC1 consists of BMI1, RING1/2, MEL-18, RAE28/MPH1, and M33/CBX2. The 
PRC1 complex binds to H3K27me3, which is established by PRC2, and stabilizes gene 
silencing by H2A ubiquitination (H2AK119ub1). Ubiquitination of H2A as the last step of 
Function Name Residues modified 
Acetyltransferase 
HAT1 H4 (K5, K12) 
CBP/P300 H3 (K14, K18), H4 (K5, K8), H2A (K5), H2B (K12, K15) 
PCAF/GCN5 H3 (K9, K14, K18) 
TIP60 H4 (K5, K8, K12, K16), H3K14 
HB01 H4 (K5, K8, K12) 
Deacetylase SirT2 H4K16 
Lysine 
Methyltransferase 
SUV39H (1-2) H3K9 
GLP/EHMT1 H3K9 
G9a/EHMT2 H3K9 
ESET H3K9 
CLL8 H3K9 
MLL (1-5) H3K4 
SET1 (A-B) H3K4 
ASH1 H3K4 
SET2 H3K36 
NSD1 H3K36 
SYMD2 H3K36 
DOT1 H3K79 
Pr-SET 7/8 H4K20 
SUV4 20H(1-2) H4K20 
EZH2 H3K27 
RIZ1 H3K9 
Lysine 
Demethylase 
LSD1/BHC110 H3K4 
JHDM1 (a-b) H3K36 
JHDM2 (a-b) H3K9 
JMJD2A/JHDM3A H3 (K9, K36) 
JMJD2B H3K9 
JMJD2C/GASC1 H3 (K9, K36) 
JMJD2D H3K9 
Arginine 
Methyltransferase 
CARM1 H3 (R2, R17, R26) 
PRMT4 H4R3 
PRMT5 H3R8, H4R3 
Serine/Thrionine 
Kinase 
Haspin H3T3 
MSK (1-2) H3S28 
CKII H4S1 
Mst1 H2BS14 
Ubiquitilases Bmi/Ring1A H2AK119 
RNF20/RNF40 H2BK120 
Proline Isomerase ScFPR4 H3 (P30, P38) 
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gene repression is thought to inhibit RNA pol II in the initiation or elongation phase of 
transcription (Radulovic, de Haan et al. 2013). Deletion of Bmi1, part of PRC1, in mice 
caused a severe reduction in the number of long-term HSCs (Park, Qian et al. 2003), whilst 
deletion of Mel-18 induced self-renewing of HSCs and a defect in B cells, suggesting a role 
for PRC1 in self-renewal and differentiation of HSCs (Akasaka, Tsuji et al. 1997, Kajiume, 
Ninomiya et al. 2004).  
Mixed Lineage Leukemia (MLL), lysine methyl transferase enzyme, plays an important role 
in the second wave of embryo hematopoiesis, AGM and further HSC development (Orkin 
2000). MLL is associated with transcriptional activation by trimethylation of H3 (H3K4me3) 
at downstream target genes, particularly HOX genes. 
Two main members of the histone demethylase family are Lysine-specific demethylase 1 
(LSD1) and the Jumonji C (JmjC) domain-containing family. LSD1 is part of a complex with 
histone deacetylases (HDACs) and CoREST and acts as a transcriptional repressor to 
downregulate expression of target genes by removing one or two methyl groups from H3K4 
or H3K9. Several JmjC domain proteins have been found including JHDM1, JHDM2, JMJD2 
and Jumonji AT-rich interactive domain 1 (JARID1). Jarid1b is highly expressed in HSCs 
and is important for HSC self-renewal (Stewart, Albert et al. 2015).  
Some histone methylations such as H3K4, H3K36, and H3K79 are linked with gene 
activation, whereas methylation on H3K9, H3K27, and H4K20 results in transcription 
inhibition. Interestingly, many promoters in stem cells co-exist alongside transcriptional 
activation (H3K4me3) and repression marks (H3K27me3). These bivalent domains allow 
stem cells to rapidly activate or silence genes during differentiation (Voigt, Tee et al. 2013). 
 
Non-coding RNA  
RNAs that do not translate to proteins are defined as non-coding RNAs, which include 
ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), small 
nucleolar RNA (snoRNA), small cajal body-specific RNA (scaRNA), piwi-interacting RNA 
(piRNA), microRNA (miRNA) and long non-coding RNA (lncRNA). Some non-coding 
RNAs, in particular miRNA and lncRNA, play a role in gene regulation and are therefore 
regarded as part of the epigenetic regulators.  
miRNAs are short RNAs containing 21-24 bases and are responsible for post-transcriptional 
gene silencing by pairing to the complement region of target mRNA and recruiting miRNA-
induced silencing complexes (miRISC) (Fabian and Sonenberg 2012). Several reports have 
 14 
shown that miRNAs play a pivotal function in hematopoiesis. In 2004, miRNA-181 was 
found to play a role as a regulatory factor in B cell differentiation (Chen, Li et al. 2004). In 
addition, growth factor independent-1 (Gfi1); a critical transcription factor for granulocytic 
differentiation is regulated by miR-21 (Velu, Baktula et al. 2009). In erythroid cell 
differentiation miR-92a and miR-17 targets regulatory erythroid genes (Li, Vecchiarelli-
Federico et al. 2012). miRNAs are not only important during differentiation but are also 
crucial in the regulation of HSPC expansion, for example overexpression of miR-17-92 
induced proliferation of multipotent hematopoietic progenitors (Li, Vecchiarelli-Federico et 
al. 2012). 
lncRNAs contain more than 200 bases and it is estimated that 10,000-60,000 lncRNAs are 
expressed in human cells (Wilkes, Repellin et al. 2017). lncRNAs regulate gene expression 
at various steps including mRNA processing, during translation or protein synthesis, 
modification of mRNA stability, miRNA inhibition and as a scaffold to facilitate mRNA 
synthesis (Geisler and Coller 2013). Numerous studies have linked lncRNAs to 
hematopoiesis. For example, over 100 lncRNAs are exclusively expressed during erythroid 
development, some of which target the transcription factors GATA, T cell acute lymphocytic 
leukemia protein 1 (TAL1) or Kruppel-like factor 1 (KLF1) (Geisler and Coller 2013). During 
myeloid development, PU.1 antisense transcript (PU.1-AS) was previously identified to 
target PU.1 mRNA and downregulates PU.1 transcription factor (Ebralidze, Guibal et al. 
2008). Similarly, HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) was identified as 
a myeloid-specific lncRNA which is highly expressed during granulocytic differentiation, 
whilst HOTAIRM1 suppresses HOXA1 and HOXA4 during myeloid differentiation (Zhang, 
Lian et al. 2009). Interestingly, more than 3000 lncRNAs have been found to be expressed 
during lymphoid development, suggesting that it is possible to characterize different 
lymphoid committed cells by the lncRNA expression patterns (Casero, Sandoval et al. 2015).  
Altogether, these studies indicate the important role of non-coding RNAs as part of the 
epigenetic regulatory compartment in HSC function and during differentiation of progenitor 
cells.  
 
1.1.4 Transcription factors involved in hematopoiesis  
Another intrinsic element which determines the identity of cells is the particular TF network 
to induce expression of lineage-specific genes. Critical TFs in hematopoiesis, contain nearly 
all groups of DNA-binding proteins rather than favoring a specific class. Some TFs are 
required for the development and maintenance of HSCs, some for the differentiation process 
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and some are involved in both. For example MLL, Runx1, TEL/ETV6, SCL/tal1 and LMO2 
are “HSCs TFs” but PU.1, Gfi-1, C/EBP𝛼 are more lineage-restricted factors (Orkin and Zon 
2008). A summary of some important TFs in hematopoiesis is depicted in Figure 5.  
 
Figure 5. Important transcription factors in hematopoiesis. Important TFs in each stage depicted 
in red. The TFs in light font have not yet been identified translocated or mutated in human/mouse 
hematologic malignancies but the rest are associated with hematopoietic malignancies. LT-HSC 
(long-term hematopoietic stem cell), ST-HSC (short term hematopoietic stem cell), CMP (common 
myeloid progenitor), CLP (common lymphoid progenitor), MEP (megakaryocyte/erythroid 
progenitor), GMP (granulocyte/macrophage progenitor) RBCs (red blood cells). Figure reprinted with 
permission from the publisher (Orkin and Zon 2008). 
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Factors required for development and maintenance of HSCs 
Development and maintenance of HSCs is pre-determined by a series of TFs, which are 
influenced by the microenvironment, signaling pathways and epigenetic regulators. During 
the emergence of HSCs, signaling molecules originating from the adjacent germ cell layer 
induce expression of crucial TFs required for this step. Therefore, physical interaction 
between primitive endoderm and adjacent mesoderm and subsequently endodermal signaling 
are required for the development of hematopoietic cells during the embryo stage 
(Belaoussoff, Farrington et al. 1998). Some important TFs required for programming the 
ventral mesoderm toward HSCs are basic-helix-loophelix (bHLH), SCL/TAL-1 and LMO2. 
The absence of these factors leads to defects in both endothelial and hematopoietic cells (Kim 
and Bresnick 2007). During the yolk stage, they are also required for development of blood 
cells, therefore they are pivotal for the development of primitive and definitive HSCs.  
One of the key TFs for definitive hematopoiesis is Runx1, which is expressed during the first 
wave of hematopoiesis in mesoderm (North, Gu et al. 1999). Zebrafish models have shown 
that Runx1, Lmo2 and Scl are regulated by Notch signaling, which induce expansion of HSCs 
(Burns, Traver et al. 2005). In adult human blood cells, Runx1 is expressed in all blood cells 
except erythrocytes (North, Stacy et al. 2004). Runx1 and Runx3 double-knockout caused 
BM failure and myeloproliferative disorder in mice via the non-transcriptional function of 
Runx in DNA repair (Wang, Krishnan et al. 2014). Apart from Runx1, another important 
factor for fetal HSCs is Sox17, which is uniquely expressed in HSCs during embryogenesis. 
Deletion of Sox17 results in a lack of adult HSCs (Kim, Saunders et al. 2007).  
Other TFs involved in hematopoiesis are HOX genes which classify in four clusters: HOXA, 
HOXB, HOXC and HOXD. HOX TFs are homeodomain-containing TFs which were 
originally characterized in Drosophila, yet with important roles in hematopoiesis (Shah and 
Sukumar 2010). They are expressed in HSCs and progenitors with specific expression profile 
patterns, dependent upon the cell lineage.  For instance HOXB3, HOXB4 and HOXA9 are 
significantly expressed in uncommitted hematopoietic cells, while HOXB8 and HOXA10 are 
activated in myeloid-committed cells (Alharbi, Pettengell et al. 2013). Overexpression of 
HOX genes most often causes HSPC expansion and blockade of differentiation. Previously, 
Hoxb6 overexpression has been demonstrated to increase the number of HSCs and myeloid 
progenitors whilst blocking erythropoiesis and lymphopoiesis (Fischbach, Rozenfeld et al. 
2005). 
The functional mechanism of HOX genes to regulate hematopoiesis is not yet clearly defined. 
However, some studies have suggested downstream targets of HOX TFs which are crucial in 
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hematopoiesis. For example, HOXA9 activates expression of other HOX genes (HOXA7 and 
HOXA10), PBX3, MEIS1, Kit, Flt3 and Sox4 which are important in hematopoiesis. Other 
important downstream target genes which are regulated by HOX genes are GATA1, C-MYC 
and RUNX2 (Alharbi, Pettengell et al. 2013). 
As mentioned above, one important upstream regulator of HOX is MLL, which directly 
regulates transcription of HOX genes. Another group of factors which directly regulate HOX 
genes are CXD genes (CDX1, CDX2 and CDX4) (Brooke-Bisschop, Savory et al. 2017). 
Deletion of Cdx1 and Cdx2 in mice was shown to impair primitive hematopoiesis and resulted 
in a lack of primitive erythrocytes as well as an abnormal yolk sac vasculature (Brooke-
Bisschop, Savory et al. 2017). Therefore, the CDX genes are also required for normal HSC 
function. 
 
Important TFs for HSCs differentiation  
Two crucial factors which are not only important for HSC generation, but also important for 
differentiation of HSCs are GATA-2 and Runx-1. Inducible deletion of Runx-1 in BM cells 
showed that Runx-1 is essential for development of megakaryocytes and T and B cell 
differentiation, but is not essential for normal myeloid development (Ichikawa, Asai et al. 
2004). Other studies, however, show that Gata2 contributes to the generation and long-term 
maintenance of HSCs (de Pater, Kaimakis et al. 2013). Several pathways upstream of Gata2 
and Runx1 regulate their expression at different stages of the HSC development and 
differentiation. The important regulatory pathways for GATA2 and RUNX1 are NOTCH 
(Guiu, Shimizu et al. 2013), BMP4 (Walmsley, Ciau-Uitz et al. 2002) and  ETS/EGR 
(Taoudi, Bee et al. 2011). There are also some myeloid factors which are expressed in GMPs 
such as C/EBP𝛼 (Orkin and Zon 2008).  
Another member of the GATA family which plays a crucial role in hematopoiesis is GATA1. 
Expression of GATA1 is important for erythropoiesis (Fujiwara, Browne et al. 1996). Specific 
deletion of Gata1 in megakaryocytes reduced platelet numbers and impaired the 
differentiation of megakaryocytes, which in turn increased numbers of immature 
megakaryocytes in the BM and spleen (Kuhl, Atzberger et al. 2005, Shivdasani, Fujiwara et 
al. 1997). Additionally, GATA1 has also been shown to have an important function in the 
development of mast cells, eosinophils, basophils, and dendritic cells (Crispino and Horwitz 
2017). 
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Activation of lineage-specific TFs determine differentiation of HSCs and usually the 
activated TFs in turn act as suppressors for other lineage-specific TFs (Orkin and Zon 2008). 
For instance, GATA-1 and PU.1 physically interact and antagonize the function of each other 
(Rhodes, Hagen et al. 2005). Expression of FOG in multipotent cells suppresses the 
eosinophil factor C/EBPbeta and yet during the eosinophil lineage commitment, C/EBPbeta 
blocks expression of FOG (Querfurth, Schuster et al. 2000). The TFs FLI-1 and EKLF cross-
antagonise their respective functions during megakaryocyte or erythroid development 
(Starck, Cohet et al. 2003). Moreover, GFI-1 physically interacts with and suppresses PU.1, 
inducing macrophage differentiation (Dahl, Iyer et al. 2007). Interestingly, in HSC 
differentiation, during the phenomenon called “the GATA switch”, GATA2 activates 
GATA1 but after activation, GATA1 negatively regulates the expression of GATA2 (Grass, 
Boyer et al. 2003).  
Altogether, the data support the fundamental role of TFs in hematopoiesis and Interestingly, 
somatic mutation or chromosomal translocations of the majority of TFs within the 
hematopoietic system are associated with hematopoietic malignancies. 
 
1.2 ACUTE MYELOID LEUKEMIA 
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy which is 
characterized by clonal expansion of abnormal or immature myeloid progenitors in the BM 
and peripheral blood (O'Donnell, Abboud et al. 2012). 
AML is the most common subtype of acute leukemia in adults, covering around 80% of all 
leukemia cases in adults (Yamamoto and Goodman 2008). The AML incidence rate is 1.3 
per 100,000 in the population younger than 65 years old and increases with age to 12.2 
patients per 100,000 in the population over 65 years old in the USA (De Kouchkovsky and 
Abdul-Hay 2016). Despite the development of therapeutic drugs and improvement of 
supportive care over the past 50 years, AML is only curative in 35-40% of adult patients 
under 60 years of age and 5-15% in patients over 60 years old (Dohner, Weisdorf et al. 2015). 
Therefore, there is a great demand for more efficient therapeutic strategies in AML. 
 
1.2.1 Diagnosis of AML  
The general symptoms of AML patients result from an accumulation of poorly differentiated 
myeloid cells in the BM and peripheral blood leading to BM failure, anemia, 
thrombocytopenia, fatigue, anorexia, fever, night sweats and weight loss. Many symptoms 
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of AML are as a consequence of normal blood deficiency due to leukemia cells outcompeting 
normal cells in the BM. Therefore, patients do not have enough RBCs, WBCs and platelets.  
Preliminary diagnosis of AML is based on morphology, notably the presence of 20% or more 
blast cells in at least 200 counted leukocytes on blood smear and 500 on speculated BM 
smear, with the exception of AML with t(15;17), t(8;21), inv(16), or t(16;16). (Dohner, Estey 
et al. 2017, Dohner, Estey et al. 2010). The nuclei of AML blasts are large in size and 
typically several nucleoli can be found in one AML cell. 
Following morphology, subsequent diagnostic methods for AML are based on surface 
phenotyping. AML cells express CD markers that exist on normal myeloid cells, such as 
CD13, CD33 and CD34 (Campos, Guyotat et al. 1989). However, other CD markers might 
be expressed on AML cells dependent upon the AML subtype or stage of AML 
differentiation (Dohner, Estey et al. 2017). For example, AML cells may express CD4, CD14, 
CD11b, CD36 and CD64 (monocyte markers), CD36, CD71 and CD235a (erythroid 
markers), CD41 and CD61 (megakaryocyte markers). Moreover, AML cells may also 
express specific T or B cells markers; CD7, CD19, terminal deoxynucleotidyl transferase 
(TdT) and human leukocyte antigen-antigen D related (HLA-DR), (Dohner, Estey et al. 
2017).  
Finally, conventional cytogenetic analysis of AML cells is the next mandatory method for 
diagnosis and classification of AML cells which is based on chromosomal abnormalities. 
Fluorescence in situ hybridization (FISH) and new sequencing technologies are used to detect 
fusion genes (McKerrell, Moreno et al. 2016), following which molecular genetic screening 
for known mutations such as NPM1, CEBPA, RUNX1, FTL3, TP53 and ASXL1 should be 
done. The summary of tests or procedures for accurate diagnosis of AML is provided in Table 
3 (Dohner, Estey et al. 2017). 
 
Table 3. Summary of tests and procedures to diagnose AML. 
 
Cellular assays  
Blood count  
Bone marrow aspirate  
Immunophenotyping  
Genetic analysis  
Cytogenetics  
Screening for mutations: NPM1, CEBPA, RUNX1, FLT3, TP53, ASXL1 
Screening for fusion genes: PML-RAPA, CBFB-MYH11, RUNX1-RUNX1T1, BCR-ABL1, MLL-X 
Additional procedures  
Medical history including exposure to toxic agents, prior malignancy and therapy, smoking  
Family history to check germ line predisposition of myeloid neoplasms  
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1.2.2 Classification of AML 
Several different classification systems have been suggested over the years based on 
morphologic analysis of blood smears and BM samples, expression levels of cell-surface or 
cytoplasmic markers using flow cytometry, cytogenetic karyotype tests and screening of 
genes that are important for AML development and maintenance. 
As of 1970, AML was classified into eight major subtypes (M0-M7) according to the French-
American-British (FAB) system, which is based on the morphology and immune phenotype 
of AML cells (Bennett, Catovsky et al. 1976). More recently, AML has been classified 
according to the world health organization (WHO) classification in 2008, which is based on 
leukemia-associated chromosomal translocations and inversions (Sabattini, Bacci et al. 
2010). According to the WHO classification, AML can be divided in seven subtypes: (1) 
AML with chromosomal abnormalities, (2) AML with myelodysplasia-related changes, (3) 
therapy-related myeloid neoplasms, (4) AML not otherwise specified (NOS) (similar to FAB 
Classification M0–M7 with others such as acute megakaryoblastic leukemia (AMKL), acute 
panmyelosis (APMF) with myelofibrosis, and pure erythroleukemia), (5) myeloid sarcoma, 
(6) myeloid proliferations related to Down syndrome, and (7) blastic plasmacytoid dendritic 
cell neoplasm (Vardiman, Thiele et al. 2009). The most recent WHO classification was 
updated in 2016 (Table 4) (Arber, Orazi et al. 2016). In the updated version, a new class 
“myeloid neoplasms with germ line predisposition” was added (Table 5); for example, 
germline CEBPA mutations frequently detected in AML patients who need special genetic 
counselling for their families (DiNardo, Bannon et al. 2016, Pabst, Eyholzer et al. 2008). 
Presently, genetic analyses of AML samples by next generation sequencing (NGS) has 
provided further information and better views into AML classification (Grimwade, Ivey et 
al. 2016, Papaemmanuil, Gerstung et al. 2016).  
AML can also be classified based on etiology into three categories: (1) de novo AML, (2) 
therapy-related AML (t-AML), and (3) secondary AML (s-AML) originated from MDS 
(myelodysplastic syndromes) or other myeloid proliferative disorder (Lindsley, Mar et al. 
2015).  
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Table 4. WHO classification of AML and related precursor neoplasms and acute leukemia. 
Table adapted with permission from the publisher (Dohner, Estey et al. 2017). 
 
AML with recurrent neoplasms 
• AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
• AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
• Acute promyelocytic leukemia with PML-RARA1 
• AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A2 
• AML with t(6;9)(p23;q34.1); DEK-NUP214 
• AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
• AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL13 
• Provisional entity: AML with BCR-ABL1 
• AML with mutated NPM14 
• AML with biallelic mutations of CEBPA4 
• Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes5 
Therapy-related myeloid neoplasms6 
AML, NOS 
• AML with minimal differentiation 
• AML without maturation 
• AML with maturation 
• Acute myelomonocytic leukemia 
• Acute monoblastic/monocytic leukemia 
• Pure erythroid leukemia7 
• Acute megakaryoblastic leukemia 
• Acute basophilic leukemia 
• Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
• Transient abnormal myelopoiesis 
• Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemias of ambiguous lineage 
• Acute undifferentiated leukemia 
• MPAL with t(9;22)(q34.1;q11.2); BCR-ABL18 
• MPAL with t(v;11q23.3); KMT2A rearranged 
• MPAL, B/myeloid, NOS 
• MPAL, T/myeloid, NOS 
 
MPAL, mixed phenotype acute leukemia; NK, natural killer. 
1. Other recurring translocations involving RARA should be reported accordingly: AML with 
t(11;17)(q23;q12); ZBTB16-RARA, t(11;17)(q13;q12); NUMA1-RARA, t(5;17)(q35;q12); NPM1-RARA, or 
AML with STAT5B-RARA. 
2. Other translocations involving KMT2A (MLL) should be reported accordingly: AML with 
t(6;11)(q27;q23.3); MLLT4-KMT2A, AML with t(11;19)(q23.3;p13.3); KMT2A-MLLT1, 
t(11;19)(q23.3;p13.1); KMT2A-ELL, t(10;11)(p12;q23.3); MLLT10-KMT2A. 
3. Rare leukemia most commonly occurring in infants. 
4. Diagnosis is made irrespective of the presence or absence of multilineage dysplasia. 
5. At least 20% blood or marrow blasts AND any of the following: previous history of MDS or MDS/MPN; 
myelodysplasia-related cytogenetic abnormality; multilineage dysplasia; AND absence of both prior cytotoxic 
therapy for unrelated disease and aforementioned recurring genetic abnormalities. Cytogenetic abnormalities 
sufficient to diagnose AML with myelodysplasia-related changes are: Complex karyotype (defined as 3 or more 
chromosomal abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, 
that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCRABL1); 
Unbalanced abnormalities: 27 or del(7q); 25 or del(5q); i(17q) or t(17p); 213 or del(13q); del(11q); del(12p) or 
t(12p); idic(X)(q13); Balanced abnormalities: t(11;16)(q23.3;p13.3); t(3;21)(q26.2;q22.1); t(1;3)(p36.3;q21.2); 
t(2;11)(p21;q23.3); t(5;12)(q32;p13.2); t(5;7)(q32;q11.2); t(5;17)(q32;p13.2); t(5;10)(q32;q21.2); t(3;5) 
(q25.3;q35.1). 
6. Cases should be classified with the related genetic abnormality given in the diagnosis. 
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7. The former subgroup of acute erythroid leukemia, erythroid/myeloid type (≥50% bone marrow erythroid 
precursors and ≥20% myeloblasts among nonerythroid cells) was removed; myeloblasts are now always 
counted as percentage of total marrow cells. The remaining subcategory AML, NOS, pure erythroid leukemia 
requires the presence of >80% immature erythroid precursors with ≥30% proerythroblasts. 
8. BCR-ABL1 leukemia may present as MPAL; treatment should include a tyrosine kinase inhibitor.   
Table reprinted with permission from the publisher (Döhner et al. 2017). 
 
Table 5. WHO classification of AML with germ line predisposition. Table adapted with 
permission from the publisher (Dohner, Estey et al. 2017). 
 
Myeloid neoplasms with germ line predisposition without a preexisting disorder or organ 
dysfunction 
• AML with germ line CEBPA mutation 
• Myeloid neoplasms with germ line DDX41 mutation1 
Myeloid neoplasms with germ line predisposition and preexisting platelet disorders 
• Myeloid neoplasms with germ line RUNX1 mutation1 
• Myeloid neoplasms with germ line ANKRD26 mutation1 
• Myeloid neoplasms with germ line ETV6 mutation1 
Myeloid neoplasms with germ line predisposition and other organ dysfunction 
• Myeloid neoplasms with germ line GATA2 mutation 
• Myeloid neoplasms associated with bone marrow failure syndromes 
• Juvenile myelomonocytic leukemia associated with neurofibromatosis, Noonan syndrome, or Noonan 
syndrome-like disorders 
• Myeloid neoplasms associated with Noonan syndrome 
• Myeloid neoplasms associated with Down syndrome1 
 
1. Lymphoid neoplasms also reported. 
 
1.2.3 Mutational landscape of AML 
Different cancer types carry various numbers of mutations but among cancers, AML is one 
of the types of cancer with the lowest number of mutations in comparison to other adult 
cancers (Figure 6) (Alexandrov, Nik-Zainal et al. 2013, Lawrence, Stojanov et al. 2013). 
Genetic alterations initially described as karyotypic abnormalities are found in roughly 50% 
of AML patients by cytogenetic analysis (Dohner, Estey et al. 2017, Medinger, Lengerke et 
al. 2016). However, almost half of AML cases do not have any karyotypic abnormalities, and 
hence are described as cytogenetically normal AML (CN-AML) patients. In CN-AML 
samples, the mean number of mutations in coding sites, splice sites and RNA genes are 
around 13 (ranging between 0-51) including eight passenger mutations and five driver 
mutations (Cancer Genome Atlas Research, Ley et al. 2013). So far, numerous mutations 
have been identified in AML patients, the most frequent of which are depicted in Figure 7. 
Below, some of the most frequent mutations which cause AML or are important in the 
development or maintenance of leukemic cells are described. 
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Figure 6. The mean number of 
mutations per genome in various 
cancer types. Figure reprinted with 
permission from the publisher (Grove 
and Vassiliou 2014). 
 
 
 
 
 
 
 
Nucleophosmin 1 (NPM1) mutations 
The nucleolar protein nucleophosmin 1 plays various cellular functions including protein 
chaperoning, centrosome duplication, DNA repair, cell proliferation and apoptosis. The most 
common mutation in AML patients is NPM1 mutations with a frequency of 25-30% in all 
AML cases and more specifically 45-64% in CN-AML (Falini, Nicoletti et al. 2007, 
Schnittger, Schoch et al. 2005). The exact mechanism of NPM1 in leukemogenesis has not 
yet been clarified. Since NPM1 has multiple functions, it is thought that NPM1 mutations 
drive leukemia through a combination of cellular processes. Loss of function due to NPM1 
mutations causes uncontrolled centrosome duplication and also promotes myeloproliferation 
and susceptibility to oncogenic transformation. Moreover, it induces ubiquitination and 
degradation of TP53 by MDM2. On the other hand, gain of function in cytoplasmic NPM1 
inhibits caspase enzymes which blocks apoptosis, induces expression of Myc and increases 
the cell proliferation rate (Heath, Chan et al. 2017).  
NPM1 mutations in AML cases are frequent in the nucleolar localization signal located at the 
N-terminal and cause abnormal expression of cytoplasmic NPM1 protein rather than in the 
nucleus. Furthermore, NPM1 mutations are correlated with DNMT3A, FLT3-ITD and +8 
(40%), FLT3-TKD (10-15%) and IDM mutations (25%) (Marcucci, Haferlach et al. 2011, 
Marcucci, Metzeler et al. 2012).  
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Figure 7.  Common gene mutations in adult AML patient up to 65 years old. For each gene, the 
frequency of correlation with other mutation s are shown in the boxes. a indicates cohesin genes 
including RAD21 (~10%), SMC1A (~5%), and SMC3 (~5%). b inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11. c inv (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); 
GATA2,MECOM(EVI1). d TP53 mutations are found in ;45%, and complex karyotypes in ;70% of 
this class. Figure reprinted with permission from the publisher (Dohner, Estey et al. 2017).  
 
Fms-like tyrosine kinase 3 (FLT3) mutations 
FLT3, a tyrosine kinase receptor for the FLT3 ligand was first found with high expression 
pattern in HSCs and plays an important role in the survival and proliferation of hematopoietic 
cells (Gilliland and Griffin 2002, Maroc, Rottapel et al. 1993). The most frequent mutations 
in FLT3 are in the second tyrosine kinase domain (TKD) or the internal tandem duplication 
(ITD) in the juxta-membrane domain, which are identified in 20% of all AML patients and 
30-45% of CN-AML cases (Kelly, Liu et al. 2002). Gain of function in FLT3 causes 
constitutive phosphorylation of some downstream proteins including GAB1, GAB2, SHP-2, 
AKT, FOXO3a, CBL, STAT5a, ERK1/2, GRB2, SHC, VAV, LYN, GAP, p90RSK, BAD, 
C/EBPα, and SHI through PI-3 kinase/AKT, RAS/ MAPK, and STAT5 pathways in 
leukemic cells (Small 2006).  
 
Isocitrate dehydrogenase (IDH) mutations  
These enzymes catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutrate. IDH1 
and IDH2 mutations were identified in 15-20% of all AML patients and 25-30% of CN-AML 
cases, most often altering the highly conserved arginine residue at codon 132 (R132) of IDH1 
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and at codons R140 and R172 of IDH2 (Marcucci, Maharry et al. 2010, Patel, Gonen et al. 
2012). Moreover, IDH1 and IDH2 mutations are also detected more in older AML patients 
(Paschka, Schlenk et al. 2010).  
Mutations of these enzymes in AML, is a gain of function, giving them a new ability to covert 
a-ketoglutarate into 2-hydroxyglutarate (2-GH). High levels of 2-GH inhibit TET enzymes, 
leading to accumulation of histone methylation, subsequently blocking myeloblast 
differentiation, and increasing stem cell marker expression, suggesting a pro-leukemic effect 
of IDH1/2 mutations (Figueroa, Abdel-Wahab et al. 2010, Lu, Ward et al. 2012, Ward, Patel 
et al. 2010).  
 
DNA methyltransferase 3A (DNMT3A) mutations 
As previously mentioned, the DNA methyltransferase DNMT3A is involved in de novo 
methylation.  DNMT3A mutations induce global hypomethylation, which is associated with 
genome instability, and hypomethylation in promoter regions of HOX and MEIS1 genes, 
which are associated with transcriptional activation (Ferreira, Heyn et al. 2016). DNMT3A 
mutations occur in 18-22% of AML patients and commonly presents as a missense mutation 
located on R882 compared to other codons in the DNMT3A gene (non-R882) (Ley, Ding et 
al. 2010). DNMT3A mutations were detected in the early stages of AML evolution as pre-
leukemic mutations and persist during remission (Shlush, Zandi et al. 2014). Yet, a large 
study of 1700 AML patients revealed that there is no significant correlation between 
DNMT3A mutations and survival (Gaidzik, Schlenk et al. 2013).    
 
Tet methylcytosine dioxygenase 2 (TET2) mutations  
TET2 is a methylcytosine dioxygenase that converts 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC), which plays key role in DNA demethylation. The most 
common type of TET2 mutation is loss of function which was found in 9-23% of AML cases 
(Chou, Chou et al. 2011), however, the prognostic effects of TET2 mutations remain 
controversial (Gaidzik, Paschka et al. 2012, Metzeler, Maharry et al. 2011).  
Tet2 mutations in mice are associated with DNA hypermethylation, altered gene expression 
patterns and subsequent increased self-renewal of HSCs and myeloid expansion (Cimmino, 
Dolgalev et al. 2017).   
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Runt-related transcription factor (RUNX1) mutations  
RUNX1, also known as AML1 protein or core-binding factor subunit a-2 (CBFA2), is a TF 
with an essential role in normal hematopoiesis (Meyers, Downing et al. 1993). Translocation 
of RUNX1 at chromosome 21 with the ETO gene on chromosome 8 creates the fusion protein 
RUNX1-ETO (RUNX1-RUNX1T1) which is frequently found in AML cases (Tang, Hou et 
al. 2009). The fusion protein RUNX1-ETO suppresses the function of normal RUNX1 in 
hematopoiesis which induces repression of myeloid-specific genes, causing a block in 
myeloid cell maturation (Ichikawa, Yoshimi et al. 2013). Moreover, other mutations in 
RUNX1 were found in 5-13% of AML cases and were frequently associated with trisomy 13, 
21, old CN-AML patients, absence of NPM1 and poor outcome (Marcucci, Haferlach et al. 
2011, Mendler, Maharry et al. 2012, Tang, Hou et al. 2009).  
 
CCAAT enhancer binding protein A (CEBPA) mutations 
CEBPA is a TF which regulates the expression of important genes required for hematopoiesis 
(Koschmieder, Halmos et al. 2009). CEBPA mutations were detected in 6-10% of all AML 
patients and 15-19% of CN-AML, generally associated with del (9q) (Mrozek, Marcucci et 
al. 2007). Conditional deletion of Cebpa in adult mice blocks CMP to GMP transition and 
consequently leads to an accumulation of myeloblasts in the BM (Zhang, Iwasaki-Arai et al. 
2004). In most AML cases with CEBPA mutations, patients often simultaneously carry two 
mutations (double mutations) commonly known as biallelic in the N-terminal and bZIP 
regions. Double biallelic mutations, but not single CEBPA mutations are associated with 
favorable overall and higher complete response (CR) (Fasan, Haferlach et al. 2014, Wouters, 
Lowenberg et al. 2009).  
 
Mixed Lineage Leukemia (MLL1) mutations  
MLL1 (Lysine-specific methyltransferase 2A or KMT2Aencodes) is a histone 
methyltransferase enzyme located on chromosome 11 (11q23). In AML, more than 80 
different protein partners were found to generate a fusion oncogene through translocation 
with MLL (Meyer, Hofmann et al. 2013). Leukemia with MLL translocations manifest as 
either acute lymphoid, myeloid or mixed phenotype acute leukemia (MPAL), which are 
detected in 10% of all leukemia cases (Muntean and Hess 2012). But the incidence of MLL 
rearrangements is 70-80% in infant leukemia patients (Mann, Attarbaschi et al. 2010).  
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Also, MLL rearrangements are common in therapy-related leukemia, typically in patients 
treated with topoisomerase II inhibitors (e.g., ectoposide, doxorubicin) (Super, McCabe et al. 
1993). Translocation of MLL is common in AML and it is correlated with poor prognosis. 
The frequencies of the main partners involved in fusion of MLL (AF4, AF9, ENL, AF10, ELL 
and AF6) in AML are shown in Figure 8. In addition to MLL translocations, partial tandem 
duplication (PTD) of MLL is most commonly identified in de novo CN-AML and in AML 
patients with trisomy 11 (Caligiuri, Schichman et al. 1994, Caligiuri, Strout et al. 1998).  
MLL rearrangements cause upregulation of several HOX genes (including HOXA5, HOXA9, 
and HOXA10) and MEIS1, which contribute to the growth advantage and maintenance of 
self-renewal properties of AML cells (Li, Luo et al. 2009). 
 
Additional sex comb-like 1 (ASXL1) mutations   
ASXL1 is a chromatin-binding protein involved in the epigenetic regulation of cells, yet the 
clear function of ASXL1 in hematopoiesis is not fully understood. ASXL1 mutations occur 
in 5-11% of all AML patients and the mutation rate is five times higher in patients over 60 
compared to those under 60 years old (Metzeler, Becker et al. 2011). ASXL1 mutations cause 
loss of H3K27me3 mediated by the PRC2 complex and upregulated expression of HOXA 
genes. Asxl1 mutations in combination with NRasG12D expression promotes myeloid 
leukemogenesis in vivo (Abdel-Wahab, Adli et al. 2012).  
 
 
Figure 8. The Frequency of MLL-rearranged AML with main seven fusion partners. The right 
pie charts show the breakdown of the relative frequencies of MLL fusion partners based on age group. 
Figure reprinted with permission from the publisher (Winters and Bernt 2017).  
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Tumor protein p53 (TP53) mutations 
TP53 regulates quiescence and self-renewal of HSCs, and so p53 mutations promote HSPC 
proliferation, leading to an accumulation of DNA damage and ultimately transformation of 
HSCs into pre-leukemic cells (Prokocimer, Molchadsky et al. 2017). Mutations of TP53 are 
reported in 8-14% of AML cases and TP53 alterations are most often associated with a 
complex karyotype, poor prognosis and resistance to chemotherapy (Haferlach, Dicker et al. 
2008, Rucker, Schlenk et al. 2012).  
 
KIT mutations 
KIT tyrosine kinase is a transmembrane receptor for mast cell growth factor (MGF) and 
critical for normal hematopoiesis (Sattler and Salgia 2004). The KIT mutation frequency is 
less than 5% in all AML patients, but identified in 22-29% of AML cases with CBF mutations 
(Paschka, Marcucci et al. 2006). Moreover, overexpression of KIT is identified in 60-80% of 
AML patients (Kindler, Breitenbuecher et al. 2004). KIT mutations are associated with a high 
relapse rate and shorter overall survival (Boissel, Leroy et al. 2006).  
KIT mutations trigger constitutive KIT kinase activation, promoting downstream signaling 
pathways which contribute to factor-independent growth of hematopoietic cells and induce 
leukemogenesis (Lennartsson, Jelacic et al. 2005). 
 
1.2.4 Prognosis factors 
A crucial component of AML treatment is an accurate assessment of AML prognosis. 
Prognostic factors can provide information for physicians to decide on a treatment strategy 
between standard or increased intensity treatment, consolidation chemotherapy or 
transplantation. Prognostic factors can be divided in two categories: patient-related, such as 
age and performance status and disease-associated factors including white-cell count, 
cytotoxic therapy for another disorder or prior myelodysplastic syndrome, cytogenetic and 
molecular aberrations (Bullinger, Dohner et al. 2017, Medinger, Lengerke et al. 2016, Meyer 
and Levine 2014).  
In 2010, the European LeukemiaNet (ELN) proposed a standardized classification of risk 
stratifications in adult AML patients according to the correlation of cytogenetic and 
molecular genetics with clinical data (Dohner, Estey et al. 2010).  In the updated 2017 
classification, patients are divided into three risk groups: favorable, intermediate and adverse. 
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(Table 6) (Dohner, Estey et al. 2017). Recently, the new techniques such as FISH, polymerase 
chain reaction (PCR) and gene sequencing have provided tools to enable a more 
comprehensive view of AML prognosis.  
In abnormal karyotype patients, alterations of chromosome 5, 7, 11q23 and more than three 
chromosomal abnormalities are associated with poor prognosis and reduced survival, whilst 
t(8;21)(q22;q22), t(15;17)(q22;q12) and inv(16)(p13.1;q22) abnormalities are associated 
with longer survival (Dohner, Weisdorf et al. 2015, Medinger and Passweg 2017). 
KIT mutations in patients with t(8;21) translocation increase the risk of relapse and decreased 
overall survival (Estey 2014, Qin, Zhu et al. 2014). The presence of TP53 or DNMT3A 
mutations are associated with poor prognosis (Kihara, Nagata et al. 2014, Shivarov, 
Gueorguieva et al. 2013). In CN-AML, partial tandem duplication of MLL is associated with 
a worse prognosis (Patel, Gonen et al. 2012).  
Several studies have shown that FLT3-ITD mutations in older CN-AML patients (>60 years 
old) are associated with poor outcome (Patel, Gonen et al. 2012, Port, Bottcher et al. 2014). 
ITD of FLT3 is associated with a poor prognosis and high relapse rate (Kelly, Liu et al. 2002, 
Meyer and Levine 2014, Saultz and Garzon 2016), constitutively activates tyrosine kinase 
and subsequently activates RAS, MAPK and STAT5 pathways and induces cell proliferation 
(Gale, Green et al. 2008, Kayser, Schlenk et al. 2009, Kelly, Liu et al. 2002). 
 
Table 6. Risk assessment of AML according European LeukaemiaNET (ELN) 2017. Table 
adapted with permission from the publisher (Medinger and Passweg 2017). 
Risk category Genetic abnormality 
Favorable 
• t(8;21)(q22;q221); RUNX1-RUNX1T1 
• Inv(16)(p131q22) or t(16;16)(p131;q22); CBFB-MYH11 
• Mutated NMP1 without FLT3-ITD or with FLT3-ITDlow (allelic ratio <0.5) 
• Biallelic mutated CEBPA 
Intermediate 
• Mutated NPM1 and FLT3-ITDhigh (allelic ratio ≥0.5) 
• Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow  (without adverse-
risk genetic lesions) 
• t(9;11)(p213;q233); MLLT3-KMT2A 
• Cytogenetic abnormalities not classified as favorable or adverse 
Adverse 
• t(6;9)(p23;q341); DEK-NUP214 
• t(v;11q233); KMT2A rearranged 
• t(9;22)(q341;q112); BCR-ABL1 
• inv(3)(q213q262) or t(3;3)(q213;q262); GATA2, MECOM (EVI1) 
• -5 or del (5q); -7; -17/abn(17p) 
• Complex karyotype (three or more unrelated chromosome abnormalities, 
monosomal karyotype (defined by the presence of 1 single monosomy) 
• Wild-type NPM1 and FLT3-ITDhigh 
• Mutated RUNX1 
• Mutated ASXL1 
• Mutated TP53 
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NMP1 mutations are associated with sensitivity to intensive chemotherapy, which may result 
in improved outcomes in both young and older patients (Dohner, Estey et al. 2017, Dohner, 
Schlenk et al. 2005). 
As a result, these three markers NPM1 mutation, CEBPA mutation, and FLT3 ITD are 
currently used in clinical practice (Dohner, Estey et al. 2010). Therefore, deep genetic 
analyses of AML patient samples are critical for prognostic classification and treatment plan 
strategies, however the ability to predict resistance to treatment and relapse remains limited 
(Walter, Othus et al. 2015).  
 
1.2.5 The bone marrow niche of AML 
Similar to normal HSCs, leukemic cells also need a proper niche in which to reside and 
expand. Recent studies have confirmed that the BM niche supports development and 
expansion of hematopoietic malignancies. Massive alterations of the BM microenvironment 
with age, in addition to mutation accumulation, contribute to leukemogenesis. For example, 
activation of the osteoblastic cell-specific parathyroid hormone (PTH) receptor enhanced 
frequency of LSCs in the MLL-AF9 AML mouse model (Krause, Fulzele et al. 2013).  
Interestingly, there is also evidence that alterations to the BM niche can induce AML. For 
instance, deletion of Dicer1 or Sbds in osteoprogenitors induced myelodysplasia and 
predisposition to AML (Raaijmakers, Mukherjee et al. 2010). Additionally, activating 
mutation of ß-catenin in osteoblast cells induces high activation of Notch signaling in 
progenitor cells, resulting in an altered differentiation of myeloid and lymphoid cells, and 
ultimately inducing AML (Kode, Manavalan et al. 2014). Altogether, these studies indicate 
that alterations to the BM niche can provide appropriate conditions which promote 
hematopoietic malignancies.  
Further studies have demonstrated that the BM niche is altered during development of CML-
blast crisis resembling AML by induction signals from the leukemic cells. It has been shown 
that leukemic cells in direct contact with MSCs secrete TPO and CCL3 that stimulate MSCs 
to overproduce functionally altered osteolineage cells which support LICs (Schepers, Pietras 
et al. 2013).  
In summary, it seems that the BM niche and leukemic cells have mutual cross-talk during 
initiation, development and AML relapse.  
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1.2.6 Clonal hematopoiesis and AML evolution  
Since HSCs divide during the whole human life, they may acquire random mutations with 
time which accumulate and are passed on to the next generation of cells. Although most 
mutations in HSCs are benign, mutations that induce enhanced self-renewal capacity or 
proliferation of HSCs and/or reduce apoptosis, cause clonal advantage.  
The two-hit model was first proposed by Gilliland and Griffin (Gilliland and Griffin 2002) 
for clonal hematopoiesis (CH) and subsequently leukemogenesis. In this model two classes 
of mutations are required. Class I mutations contribute to the activation of proliferation 
pathways or to survival advantage such as FLT3-ITD, K/N-RAS, TP53 and c.KIT. Whereas 
class II mutations impair normal differentiation of hematopoietic cells such as NPM1, 
CEBPA, PML/RARa and MLL fusion genes. In addition to these two classes of mutations, 
there are some mutations of epigenetic factors such as DNMT3A, TET2, IDH1 and IDH2 
which effect both proliferation and differentiation, and so can be classified in to a third group 
(De Kouchkovsky and Abdul-Hay 2016).  
Additionally, other mechanisms such as the immune system, BM niche alterations and 
selective pressure on somatic variants (aging, chemotherapy and exogenous stress such as 
smoking) also influence CH (Bowman, Busque et al. 2018). The most common mutations 
present in CH are in epigenetic factors like TET2, DNMT3A and ASXL1 and splicing factors 
such as SF3B1, SRSF2 and U2AF1 (Bowman, Busque et al. 2018). These mutations in CH 
prime them to develop hematopoietic malignancies.  
Mutations that contribute to cancer initiation and growth are called driver mutations, whilst 
those that do not affect cancer growth are termed passenger mutation. However, the 
classification of cancer depends on its microenvironment. For example, certain AML 
mutations can confer drug resistance so that during cancer treatment sub-clones carrying 
these mutations can survive and expand, whereas in the absence of treatment these mutations 
might have a growth disadvantage effect (Grove and Vassiliou 2014). On the other hand, 
some passenger mutations may be selected in a specific microenvironment condition and 
induce drug resistance or growth advantage.  
Cancer evolution similar to Darwinian natural selection was first suggested by Peter Nowell 
(Nowell 1976). Emerging data from AML patient samples using new technologies, 
particularly NGS, are providing a better view of mutational frequencies, clonal evolution of 
the disease, sub-clonal patterns and into the epigenetic landscape of AML. The result from a 
clonality analysis of 50 whole genome sequences and 150 whole-exomes sequences of AML 
patient samples revealed that the majority of AML cases are clonally heterogeneous with a 
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founding clone and at least one sub-clone at the diagnosis stage (Cancer Genome Atlas 
Research, Ley et al. 2013). Importantly, two major clonal evolution patterns during relapse 
were determined: either a founding clone or a surviving sub-clone acquired additional 
mutations most likely contributed to drug resistance and expanded at relapse stage (Ding, 
Ley et al. 2012). 
New findings from NGS of pre-leukemic stem cells and clonal evolution of AML revealed 
that pre-leukemic HSCs already contain recurrent common mutations in epigenetic 
regulators, such as DNMT3A, ASXL1, IDH1, IDH2, and TET2. They are therefore thought to 
occur in the early stage of AML evolution (Corces-Zimmerman, Hong et al. 2014, Kronke, 
Bullinger et al. 2013, Shlush, Zandi et al. 2014). Moreover, the frequency of somatic 
mutations (DNMT3A, TET2, and ASXL1) were rare in individuals under 40 years old but 
increased with age and the presence of these mutations was associated with a higher risk of 
hematologic cancers (Busque, Patel et al. 2012, Genovese, Kahler et al. 2014, Jaiswal, 
Fontanillas et al. 2014). Other somatic mutations which are known in AML are FTL3, NPM1, 
WT1, RUNX1, RTRP, PHF6 and ETV6 (Zhang, Lv et al. 2016). 
 
1.2.7 Leukemic stem cells   
A small population of cells amongst AML blast cells, have limitless self-renewal capacity 
and the ability to propagate and go on to develop AML. These cells are known as leukemic 
stem cells (LSCs) or leukemia initiating cells (LICs). LICs are a rare population (roughly 1 
per 106 bulk) in many AML patients capable of initiating leukemia in immunodeficient mice 
and maintaining long-term in serial transplanted mice with self-renewing capacity. There is 
some evidence showing that LICs are not only originated from HSCs, but certain mutations 
in differentiated cells may also transform them in to LSCs (Cozzio, Passegue et al. 2003, 
Huntly, Shigematsu et al. 2004).  
The critical step of LIC detection is to define markers which are associated with functional 
properties of LICs. LICs usually exist in the CD34+CD38- fraction of AML cells in patients 
(Lapidot, Sirard et al. 1994). However in more than 50% of samples LICs reside in 
CD34+CD38+ or even the CD34- population (Kreso and Dick 2014). Further experiments 
revealed in 80% of AML patients LSCs exist in both fractions; LMPP-like (lymphoid-primed 
multipotent progenitors) LSCs (Lin-CD34+CD38-CD90-CD45RA+) and GMP-like LSCs 
(Lin-CD34+CD38+CD123+CD45RA+). Interestingly, LMPP-like LSCs could give rise to 
GMP-like LSCs but not the converse (Goardon, Marchi et al. 2011).  
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From a clinical perspective, to achieve long-term complete remission (CR), it is critical to 
eliminate LICs. However, there are several obstacles to target LICs with conventional 
therapies. First, there is no standard method to characterize LICs which demonstrate their 
properties. Secondly, LICs are a rare population and quiescent so it is difficult to eliminate 
them with current drugs which target proliferative bulk cells. Thirdly, LICs are usually 
resistant to apoptosis and they highly express channels for drug efflux (Thomas and Majeti 
2017). In addition, recent studies have shown heterogeneity in LICs both between and within 
individual patients (Eppert, Takenaka et al. 2011, Goardon, Marchi et al. 2011). Thus, it is 
needed to identify new targets against LICs to develop more effective therapies.  
 
1.2.8 AML treatment  
Current therapy 
The common therapeutic approach in AML patients not much has changed since 1970 
(Dohner, Estey et al. 2010). The first line of treatment is to assess whether intensive 
chemotherapy is suitable for a AML patient. After intensive therapy, post-induction therapy 
is important to achieve CR. Two types of post-induction strategies are: conventional 
chemotherapy and hematopoietic cell transplantation. 
 
Induction therapy 
The aim of induction therapy is to diminish AML cells and achieve CR. The standard 
induction therapy is chemotherapy. Intensive induction therapy is applicable to young adult 
AML patients under 60 years old and older patients specifically with NPM1 mutations and 
CBF leukemia (Saultz and Garzon 2016). The standard chemotherapy protocol is the “7+3” 
regimen with a combination of continuous infusion of cytarabine (100 mg/m2 daily for one 
week) and an anthracycline (either daunorubicin 60-90 mg/m2 or idarubicin 10-12 mg/m2 on 
days 1, 2 and 3). The current conventional therapies for AML patients are summarized in 
Table 7.  
The CR rate is 65-73% in adult patients younger than 60 years and 38-62% in patients over 
60 years old (Estey and Dohner 2006, Fernandez, Sun et al. 2009, Lowenberg, Ossenkoppele 
et al. 2009). CR is defined as (1) <5% blasts in a BM aspirate sample with marrow spicules 
(no blasts with Auer rods or persistence of extramedullary disease), (2) absolute neutrophil 
count (ANC) >1000/µl, and (3) platelets ≥100,000/µl (Cheson, Bennett et al. 2003).  
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Consolidation (post-induction) therapy 
The aim of consolidation strategies is to eradicate minimal residual disease (MRD), prevent 
relapse and ideally to achieve a complete cure with either chemotherapy or transplantation. 
MRD can be monitored by using molecular based approaches such as real-time quantitative 
PCR (RT-qPCR) or target gene sequencing to detect genetic targets specific to AML cells 
and/or multi-parameter flow cytometry (MFC) to read-out leukemic cells based on their 
immune phenotype (Grimwade and Freeman 2014).  
In consolidation chemotherapy, intermediate dose of cytarabine (1-1.5g/m2) is used twice 
daily on days 1, 3 and 5 in three or four cycles in adults younger than 60 years old, where the 
cure rate is 60-70% (Byrd, Mrozek et al. 2002). However, in patients older than 60 years, the 
cure rate is dismal, between 10-15%, therefore new strategies of maintenance therapies need 
to be investigated (Dohner, Weisdorf et al. 2015).  
Hematopoietic stem cell transplantation is a treatment strategy for patients who are unlikely 
respond to the conventional induction therapy and to extend CR. Prior to transplantation, 
chemoradiotherapy is chosen to deplete leukemic cells, suppress the immune system, and to 
 
Table 7. Summary of current conventional care of AML patients. Table adapted with 
permission from the publisher (Dohner, Weisdorf et al. 2015).  
 
 
Type of therapy Age Regimen 
Induction therapy 
Patients 16–60 yr 
3 days of an intravenous anthracycline (daunorubicin 60 
mg/m2; idarubicin 10-12 mg/m2; mitoxantrone 10-12 mg/m2) 
and 7 days of continuous-infusion cytarabine (100-200 mg/m2) 
(“3+7” induction) 
Patients >60 yr 
For patients with favorable-risk and intermediate-risk 
cytogenetic findings and no coexisting conditions, induction 
therapy is the same as that in younger patients, and dose 
reduction may be considered for individual patients 
Consolidation 
therapy 
Patients 16–60 yr 
Patients with favorable genetic risk (according to ELN) should 
Receive 2-4 cycles of intermediate-dose cytarabine (1-1.5 g/m2 
intravenously, usually administered every 12 hr over 3 days, or 
1-1.5 g/m2 intravenously on days 1-6); for patients with 
intermediate-I, intermediate-II, or adverse risk, allogeneic 
hematopoietic-cell transplantation should be strongly 
considered; if not possible, consolidation therapy should be 
administered as above; combination chemotherapy (e.g., 
mitoxantrone-cytarabine) may be superior in patients with 
adverse-risk AML 
Patients >60 yr 
Patients with favorable ELN genetic risk (less common) and no 
coexisting conditions should receive 2-3 cycles of 
intermediatedose cytarabine (0.5-1 g/m2 intravenously, every 
12 hr on days 1-3, or 0.5-1 g/m2 intravenously, on days 1-6) 
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provide space for donor cells in in the BM. The most common regimen for 
chemoradiotherapy is fludarabine in combination with cyclophosphamide or other alkylating 
reagents (such as melphalan and busulfan) and total-body irradiation. The key dilemma after 
transplantation is graft-versus-host-disease (GVHD), in which donor immune cells recognize 
the host cells as foreign and attack the recipient’s organs. Therefore, accurate HLA matching 
is required to decrease the risk of GVHD.  
Despite new techniques such as NGS to predict prognosis and to improve treatment strategy 
selection, the heterogeneity of AML and the varied genetic landscape of sub-clones make it 
difficult to estimate the risk of relapse.  
 
Novel treatment strategies  
Since AML is a heterogeneous disease within patients and even within sub-clones, the 
standard chemotherapy strategy is not the best option for all patients and given that 
chemotherapy does not specifically target leukemic cells, it is known to cause severe side 
effects. Personalized medicine (also known as precision medicine) is the new goal in the 
cancer field, which refers to individual patient based-strategies, where their genetic 
background, prognosis and predicted response and treatment strategies are tailored to each 
individual patient. However, it is demanding to design new drugs or inhibitors specifically 
targeting driver genes in cancer cells for treatment based on the mutational background to 
improve cure rate, increase survival rate and prevent relapse. Here, new inhibitors and 
treatment strategies in AML are briefly described. 
 
FLT3 Inhibitors 
The first generation of multiple kinase inhibitors such as midostaurin, lestaurtinib, tandutinib, 
sunitinib and sorafenib, have recently shown transient reduction of leukemic cells and 
increased toxicity (Sudhindra and Smith 2014). The second generation of FLT3 inhibitors 
including quizartinib and crenolanib are being used in the clinical phase and have better 
potency with less side effects. However, drug resistance is a main obstacle when using single 
inhibitor for FLT3 mutations. Recently, the drug Midostaurin was approved by the FDA to 
be used in combination with daunorubicin and cytarabine for FTL3 mutation positive AML 
patients. Additionally, G-749 and ASP2215, as novel FLT3 inhibitors with a decreased risk 
of drug resistance, have recently been used in clinical trials (Lee, Kim et al. 2014). 
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IDH Inhibitors 
In 20% of AML samples IDH-1 or IDH-2 have gain of function mutations (Cancer Genome 
Atlas Research, Ley et al. 2013). There are some IDH1 and IDH2 inhibitors currently in 
phase I and II clinical trials, such as NCT02381886, NCT0195498 and NCT02074839, AG-
221 and AG-120, CB-839, Erwinaze (Fathi, Wander et al. 2015, Medinger and Passweg 
2017). The response rates in relapsed patients to AG-221 and AG-120 was 40% and 31% 
respectively.  
 
HDAC inhibitors 
Epigenetic modifiers HDACs catalyze deacetylation of histones and involve in gene 
silencing. Mutations or dysregulations of many acetyltransferases and deacetylases have been 
identified in leukemia including p300, CBP, AML1. Therefore, HDAC inhibitors including 
varinostat, mocetinostat and SAHA appeared as an attractive therapeutic strategy for AML. 
Since the response rate in monotherapy studies using single HDAC inhibitors were low (13-
17%), the current trial strategies focus on combination of HDAC inhibitors with 
chemotherapy or other epigenetic inhibitors (Saygin and Carraway 2017). 
 
STAT inhibitors 
Deregulation of STAT signaling in AML is associated with an increased expansion, apoptosis 
block and abnormal differentiation of leukemic cells. Constitutive activation of STAT3 and 
STAT5 either alone or together has been reported in AML patients (Bar-Natan, Nelson et al. 
2012). Furthermore, STAT3 tyrosine phosphorylation is associated with a worse prognosis 
and was found to be upregulated in 50% of AML patients (De Kouchkovsky and Abdul-Hay 
2016). Moreover, overexpression of STAT3 signaling contributes to FLT3 inhibitor 
resistance in AML cells (Zhou, Bi et al. 2009). Therefore, STAT3 inhibitors such as OPB-
31121 could be used for patients who are being treated with FLT3 inhibitors.  
 
MLL inhibitors 
There are many approaches to target MLL fusion proteins in AML patients with MLL 
translocations. One target is Disruptor of telomeric silencing 1-like (DOT1L), a histone 
methyltransferase, which is recruited by most of the MLL fusion proteins. Abnormal 
interaction of MLL oncogene and DOT1L results in methylation of H3K79 and activation of 
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MLL downstream target genes including HOXA9 and MEIS1 (Kavanagh, Murphy et al. 
2017). Other inhibitors against Menin, Polycomb proteins, LSD1 and Bromodomain proteins 
can be used to target MLL-rearranged leukemias (Winters and Bernt 2017).  
 
Nuclear Exporter Inhibitors 
Chromosome region maintenance 1 (CRM1) is a nuclear exporter protein which is 
responsible for exporting several tumor suppressor proteins such as P53, P21, P73, FOXO1, 
RB1 and NMP1 (Fukuda, Asano et al. 1997). Overexpression of CRM1 causes exorbitant 
transportation of tumor suppressor proteins from the nucleus to the cytoplasm, which is 
associated with poor prognosis and decreased survival (Kojima, Kornblau et al. 2013). 
Selinexor as a CRM1 inhibitor is in clinical trials to be used as a drug for AML patients with 
high CRM1 expression levels (Etchin, Sun et al. 2013, Ranganathan, Yu et al. 2012).  
 
Clofarabine 
Clofarabine is a second-generation purine nucleoside analogue FDA-approved for treating 
relapsed or refractory childhood ALL patients. Clofarabine enters cells via passive or active 
transport and is transformed to its active triphosphate form by kinases. Clofarabine inhibits 
both DNA polymerase and ribonucleotide reductase, which in turn inhibits DNA replication 
as well as RNA transcription (Tiley and Claxton 2013). Treatment of older AML patients 
with Clofarabine resulted in a 40% overall response rate (Burnett, Russell et al. 2013, 
Kantarjian, Erba et al. 2010). Combination of Clofarabine with a low dose of cytarabine 
significantly increased the CR rate from 31% to 63% in patients over the age of 60 (Faderl, 
Ravandi et al. 2008). 
 
Immune and Cell Therapies 
A new strategy of induction therapy is immune therapy using an anti-CD33 antibody, which 
in testing showed a similar response rate compared to chemotherapy treatment but reduced 
risk of relapse and increased survival. The transmembrane receptor CD33 is expressed on 
cells of myeloid origin but not on normal HSCs. Widespread expression of CD33 in AML 
cells promoted the idea of targeting CD33 to treat AML patients (Appelbaum and Bernstein 
2017). A humanized anti-CD33 monoclonal antibody (Gemtuzumab ozogamicin) conjugated 
with the cytotoxic agent calicheamicin was tested in five randomized trials and approved by 
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the FDA in 2000 (Hills, Castaigne et al. 2014). Although further clinical trials in 637 patients 
failed to show improvements in CR or overall survival (Petersdorf, Kopecky et al. 2013), 
recent trials showed a benefit in survival and relapse rates in old AML patients not eligible 
for intensive chemotherapy and also in patients with an intermediate to favorable cytogenetic-
risk pattern (Amadori, Suciu et al. 2016).  
Another new cell therapy strategy is to use engineered T cells called chimeric antigen 
receptor (CAR)-transduced T cells (CARTs) to express antigen receptors against specific cell 
surface antigens in target AML cells. One type of CARTs in preclinical trials is against 
CD123, which is expressed on the majority of AML cells (Gill, Tasian et al. 2014). CD33-
specific CART cells showed improved survival in a xenograft AML mouse models 
(Kenderian, Ruella et al. 2015). New therapeutic agents in ongoing clinical trials for AML 
treatment are listed in Table 8.  
 
Table 8. Summary of new therapeutic agents in ongoing clinical trials. Table adapted with 
permission from the publisher (Yu and Zheng 2017). 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agent Name Target Phase of testing 
Molecular antibody 
Gemtuzumab ozogamicin CD33 I, II, III 
Vadastuximab 
talirine (SGN-CD33A) 
CD33 I, II 
AMG 330 CD33 I 
HuM195 CD33 I, II 
Yttrium Y 90 anti-CD45 
monoclonal antibody 
BC8 (90Y-BC8) 
CD45 NA 
KB004 EphA3 I, II 
Ipilimumab CTLA-4 I 
Brentuximab CD30 I, II 
Ulocuplumab CXCR4 I 
FLT3 inhibitors 
Lestaurtinib FLT3 I, II 
Midostaurin FLT3 I, II, III 
Sorafenib FLT3 I, II, IV 
Quizartinib FLT3 I, II, III 
Crenolanib FLT3 I, II, III 
Gilteritinib FLT3 II, III 
Pexidartinib (PLX3397) FLT3 I, II 
AURK inhibitors Alisertib AURKA I, II 
mTOR kinase 
inhibitors 
Sirolimus mTOR I, II 
Temsirolimus mTOR I, II 
Everolimus mTOR I, II 
Epigenetic agents 
Decitabine Methyltransferase I, II, III 
Azacitidine Methyltransferase I, II 
Vorinostat Histone acetylase I, II 
Panobinostat Histone acetylase I, II 
CAR-T cell therapy CAR-T33 CD33 I, II CAR-T123 CD123 I, II 
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1.2.9 Childhood AML 
Among all AML cases, 6% of them develop in childhood (Dores, Devesa et al. 2012) and 
20% of pediatric leukemic cases are AML (Yu and Zheng 2017). The survival rate of AML 
in patients under 20 years old have improved during the last 40 years from 20% in 1980 to 
70% in 2012 of AML cases, but the clinical outcomes of childhood AML in many subtypes 
remains low (Gamis, Alonzo et al. 2013, Rubnitz and Inaba 2012, Rubnitz, Inaba et al. 2014).  
Certain mutations common in adult AML are rare in childhood AML and vice versa, 
suggesting differing mechanisms and pathogenesis of AML in adults and children. The main 
molecular aberrations in childhood AML are depicted in Figure 9. The major differences 
between childhood AML compared to adult AML are a significantly higher frequency of 
MLL-related leukemia, particularly in patients under two years old, and a lower incidence of 
cytogenetic abnormalities (Cooper, Franklin et al. 2012). Therefore, the role of molecular 
risk factors such as FLT3-ITD, IDH1 and DNMT3 mutations is more prominent in childhood 
AML cases (Ho, Alonzo et al. 2010, Ho, Kutny et al. 2011, Meshinchi, Alonzo et al. 2006). 
Furthermore, pediatric AML patients are typically able to tolerate more intensive therapy, 
which affects the overall outcome compared to adult AML patients.  
 
 
Figure 9. Frequency the main cytogenetic (A) and molecular (B) abnormalities identified in 
childhood AML younger and older that 2 years old. Figure reprinted with permission from the 
publisher (Masetti, Vendemini et al. 2015). 
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2 AIM OF THE THESIS 
The overall aim of the thesis was to identify and characterize novel effectors and pathways 
important in maintenance of AML and in normal hematopoiesis.  
The specific aims were:  
 
Study I: 
Identify and characterize novel target genes that are specifically required for the maintenance 
of AML but not normal hematopoietic cells.  
 
Study II: 
Identify and characterize novel transcriptional regulators important in the maintenance and 
disease progression of AML.  
 
Study III: 
To investigate the role of the epigenetic enzyme EHMT1 in AML.  
 
Study IV: 
To investigate if targeting SAMHD1 represents an attractive therapeutic approach to 
potentiate the effects of ara-C treatment in hematological malignancies.  
 
Study V: 
To determine the role of the epigenetic factor NAP1L3 in HSCs and hematopoiesis. 
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3 METHODOLOGICAL APPROACHES 
3.1 LENTIVIRAL TRANSFECTION AND TRANSDUCTION 
For lentivirus production, The adherent 293FT cells were co-transfected with the vectors, 
pAX8 and pCMV-VSVG, using the calcium phosphate transfection method (Kingston, Chen 
et al. 2003). Briefly, the 293FT cells were split in 10 cm dishes on the day before transfection 
and the cells fed with 9 ml DMEM media containing 10% FBS 4 hours before transfection. 
For the transfection 10 µg vector DNA, 8 µg pAX8 and 4 µg pCMV-VSVG were mixed with 
64 µl of 2 M CaCl2 and water was added up to 500 µl. 500 µl HEPES was added into a 5 ml 
FACS tube and the DNA/CaCl2 solution added dropwise with a pipette whilst simultaneously 
aerating the mixture by constantly bubbling with a mechanical pipettor attached to a 1 ml 
pipette and then the mixed solution was immediately vortexed for 5 seconds. The precipitate 
was incubated for 10 minutes at room temperature and 1 ml of the mixed solution was added 
to a 10 cm plate, covering almost everywhere and incubate for 6 hours or overnight. The 
medium was replaced with 6 ml of medium suitable for the target cells for transduction, and 
the transfected plates were incubated at 32℃ to produce virus. Virus supernatant was 
harvested 24 h and 48 h post transfection and was concentrated by centrifugation at 6000 x g 
for 16 h at 4℃.  
The AML cells and normal hematopoietic cells were transduced with the virus supernatant 
by spinoculation, i.e. by centrifugation of a mixture of cells and virus for 2 h at 1000 x g in 
6 or 12 well non-tissue treated plates. Transduced cells were selected by adding puromycin 
at the final concentration of 2 µg/ml for 48 h.  
 
3.2 LARGE SCALE SHRNA SCREEN 
RNA interference (RNAi) was first discovered in Caenorhabditis elegans as double stranded 
RNA-mediated gene silencing. Double stranded RNA (dsRNA) is a substrate for Dicer 
(RNAse III enzyme) that produces 20-25 bp dsRNA, which is recognized by the RNA-
induced silencing complex (RISC). RISC destroys the “passenger strand” and keeps the 
“guiding strand”. The RISC complex and guiding strand bind to target mRNA and digest it, 
resulting in post-transcriptional gene silencing (Gao, Yang et al. 2014).  
The major challenge in molecular biology is to find out the functional role of genes in specific 
strains of cells. RNAi technology (Fire, Xu et al. 1998) is a tool to silence target genes and 
investigate the role of the gene. The advantage of RNAi is the ability to investigate the role 
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of a gene based on the phenotype-associated loss of function. Therefore, RNAi has become 
the appropriate method for functional genomics, signal transduction, and drug target 
discovery assays. In the cancer field, using RNAi technology helps to identify oncogenes 
which are essential for cancer cell survival and to find target genes for cancer treatment. Also, 
it is possible to pool individual RNAi and make libraries for genome-wide or high-throughput 
screens (HTS) to quickly and simultaneously screen multiple genes. Firstly, the readout of 
RNAi HTS should be well-defined such as proliferation, apoptosis or cell morphology. 
Similarly, a proper and easy phenotypic assay should be defined based on the readout. 
We used two libraries: library module 1 including 27,500 shRNAs (short hairpin RNAs) 
against 5,000 signaling pathway genes for study II and library module 2 including 27,500 
shRNA targeting disease-associated genes in study I. Each individual shRNA contained a 
unique barcode. 
In studies I and II, we used lentiviral vector-based shRNA screens. To ensure we have enough 
cells per individual shRNA (>1000 cells/shRNA), we cultured approximately 3x108 of 
several AML cell lines (THP-1, NOMO-1, and the mouse MLL-AF9 AML) with a 
concentration of 250,000 cells/ml which were transduced with pooled lentiviral shRNA 
libraries. To minimize the number of cells with multiple viral integrations, we kept the 
transduction efficiency at less than 25%, as determined by flow cytometry to measure RFP+ 
cells. After 48 h of transduction, we added puromycin (2µg/ml) to select transduced cells, 
after which, half of these were collected for an initial time point (T0) where the selection 
control cells were completely dead. The rest of the cells were harvested after 10 cell divisions 
(T10) in culture. Genomic DNA was extracted from T0 and T10 cells by QIAgene DNA 
extraction kit according to the manufacturer’s instructions, and the barcodes were amplified 
from the extracted genomic DNA using nested PCR according to Cellecta’s protocols. PCR-
amplified barcodes were purified using the QIAgene PCR purification kit and used for NGS 
(HiSeq 2000, Illumina). Barcodes were deciphered using Cellecta’s software to detect the 
number of reads per barcode, which represented the frequency of individual shRNAs 
targeting specific genes at T0 and T10. After normalization of reads between samples, the 
ratios of individual barcodes were calculated by dividing T10/T0.  
There are three possibilities for each shRNA according the ratio number. If the ratio of 
T10/T0 is >1, it means that the target gene was a growth suppressor and by knocking down 
the gene the cells containing the shRNA proliferate more. The second scenario is that T10/T0 
is equal to 1, meaning that the target gene did not influence cell growth and finally, the third 
possibility is that ratio of T10/T0 <1, meaning that the target gene has an important role in 
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cell growth. We selected the shRNA targeting genes from the third scenario with at least 5-
fold reduction (T10/T0 <0.2) in AML cell growth for further validations.  
 
3.3 CRISPR/CAS 9 GENOME EDITING 
The clustered regularly interspaced short palindrome repeats (CRISPR)/Cas9 technology is 
a new gene editing system. CRISPR/Cas9 acts as an adaptive immune system in bacteria for 
cleaving foreign genetic elements such as viruses and plasmids via RNA-guided nucleases 
(Deveau, Garneau et al. 2010). Cas9 (a non-specific CRISPR-associated endonuclease 9) is 
guided by small RNA “gRNAs” to the target DNA sequences. CRISPR systems have been 
divided into two major classes based on their components and mechanisms of action. Class 
1 including type I, III and IV involve several effector proteins but class 2 (type II, V and VI) 
only requires one RNA-guided endonuclease (Wang, La Russa et al. 2016). Cas9 is guided 
to target DNA by two hybridized RNAs: crRNAs, that identifies target DNA through a 20 
base pair (bp) recognition sequence and tracrRNAs, which hybridizes with the crRNAs. To 
simplify the system for genome editing, crRNA and tracrRNA, can be engineered as a single 
chimeric guide RNA (sgRNA) (Jinek, Chylinski et al. 2012). The most widely used Cas9-
based genome editing system is a single protein Cas9 with a single RNA sgRNA (Cas9-
sgRNA) which binds to 20 bp target DNA adjacent to a protospacer adjacent motif (PAM) 
sequence (Figure 10). 
 
 
Figure 10. Schematic of the RNA-guided Cas9 nuclease. protospacer adjacent motif (PAM), non-
homologous end joining (NHEJ), homology-directed repair (HDR). Figure reprinted with permission 
from the publisher (Cui, Xu et al. 2018).  
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CRISPR/Cas9 tools edit the genome via two mechanisms: non-homologous end joining 
(NHEJ) or homology-directed repair (HDR) (Figure 9). In the absence of a repair template, 
the Cas9 enzyme creates DNA double strand breaks (DSBs) and re-ligates through the error-
prone NHEJ process, often producing an insertion/deletion or single nucleotide mutation, 
which result in frameshifts and eventually gene knockout. HDR is another DNA repair 
pathway which uses a repair template which can be used to induce precise and defined gene 
modification at a target site.  
Lastly, since CRISPR/Cas9 is flexible and robust technique, it is becoming attractive tool to 
use not only for genome editing but for various genome modification applications including 
gene regulation (silencing or activation), epigenome editing, chromatin imaging, chromatin 
topology, RNA targeting (Figure 11).  
 
 
Figure 11.  Main applications of CRISPR/Cas9 technology. Figure reprinted with permission from 
the publisher (Adli 2018). 
 
For CRISPR/Cas9-mediated knockout studies, gRNAs were designed from Optimized 
CRISPR Design - MIT (http://crispr.mit.edu) provided by the Zhang laboratory and were 
cloned into the vector for inducible expression pRSITEP-U6Tet-(sh)-EF1-TetRep-2A-Puro 
expressing fluorescent marker (GFP, BFP, or iRFP670).  
First, we developed a stable Cas9 expressing AML cell lines by transducing AML cells with 
a constitutive expression vector for the Cas9-mCherry fusion protein kindly provided by 
Marco Herold (Aubrey, Kelly et al. 2015). Then, the transduced cells (Cas9-mCherry+) were 
sorted using a BD Fusion BSL2 flow cytometer and expanded in culture. For the desired 
knockout studies, the stable AML cell line expressing Cas9-mCherry was transduced with 
gRNA vectors expressing either GFP, BFP or iRF670. For tracking the cells with Cas9-
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sgRNA, flow cytometry analysis was used to detect double positive cells for example 
mCherry+iRFP670+.  
 
3.4 FLOW CYTOMETRIC ANALYSIS AND SORTING 
Flow cytometry is a potent tool to characterize cells based on size, granularity and 
fluorescence emission of a targeted antibody. The first flow cytometry analysis was 
developed in 1956 to detect the size of the cells and in 1980 the first clinical application of a 
fluorescent activated cell sorter (FACS) was used by researchers to detect lymphocyte subsets 
(Wilkerson 2012).  
The basic principle of a flow cytometry instrument is characterization of cells in a fluid 
stream passing the cells through the beam of a light source (laser). Therefore, the main 
components of almost all flow cytometers or cell sorters are: fluidics to direct sheath buffer 
(phosphate-buffered saline) containing cells to the flow chamber (where the laser beams are 
located) by pressurized lines, optics including excitation and detection, an electronic network 
to convert light or fluorescent signals coming from the cells into digital signals and a 
computer to record digital signals (Figure 12A).   
 
 
Figure 12.  Overview of flow cytometer (A) and sorter (B). Figure reprinted with permission from 
the publisher (Adan, Alizada et al. 2017).  
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Flow cytometry is used to characterize cells based on detection of their surface-bound, 
cytoplasmic and nuclear antigens. Moreover, it is possible to investigate cellular components 
such as organelles, nuclei, DNA, RNA, cytoplasmic protein, nucleus proteins using flow 
cytometry.  
The principle of cell sorting is an electrostatic deflection of charged droplets containing 
individual fluorescent cells. Flow sheath buffer containing cells is injected through a 
vibrating nozzle that break up the stream into droplets surrounding individual cells. Then, the 
droplets pass through one or more laser beams to characterize the cell population of interest 
and simultaneously, the tagged droplets are charged by a charging electrode. Then a platinum 
plate of negative charge deflects positively charged droplets and a positively charged 
platinum plate deflects negatively charged droplets and uncharged droplets goes into the 
waste container. Single or multiple parameters can be used for sorting the desired cell 
population and to collect them for further assays (Figure 12B).  
Here flow cytometric analysis was performed with a 4-laser BD LSRFortessa.  
To analyze primary childhood and adult AML cells after ex vivo culture, the cells were 
harvested and incubated with anti-mouse (Biolegend) and human (ChromPure Mouse IgG, 
Jackson ImmmunoResearch) CD16/32 (Fc-block) antibodies for 20 minutes on ice to block 
unspecific receptors. Then the cells were stained for 20 minutes with anti-human CD45 to 
distinguish human AML cells from mouse stromal feeder cells, lineage antibodies (CD20, 
CD4, CD8, CD2, CD56, CD235b, CD3 and CD19) to exclude mature cells and CD34, CD38 
to identify LICs. Dead cells were excluded using the Near-IR Live/Dead marker (Invitrogen). 
To count the absolute number of AML cells in each well from 96-well plate format, we used 
a high-throughput automated plate reader (BD LSRFortessa).  
To detect cells with a specific fluorescent marker mixed with control cells from cell growth 
competition assays, cells were harvested and washed with cold PBS and thereafter stained 
with Near-IR Live/Dead marker in a 96-well plate in 80 µl of PBS and 2% FBS. A high-
throughput automated plate reader was used to detect the absolute number of live cells.  
For in vivo studies, and to determine the level of engrafted human AML cells in transplanted 
NSG-SGM3 mice, the BM cells were isolated by crushing the tibia and femur of recipient 
mice. The isolated BM cells were incubated in mouse and human FC blocking antibodies for 
10 minutes on ice, then stained with human anti-CD45 for 20 minutes. Near-IR Live/Dead 
marker was used to detect live cells. To analyse the different types of mature human cell 
populations in NSG-SGM3 transplanted mice, the BM cells were isolated and stained with 
CD11b, CD14, CD56, CD19, CD33, CD16, CD3, HLA-DR and CD45.  
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To determine engraftment of mouse CD45.1+ cells in recipient CD45.2+ mice, the BM cells 
were isolated from tibia and femurs of recipient mice. The isolated cells were then incubated 
10 minutes with mouse FC blocking antibody (anti-CD16/CD32), then 20 minutes with 
mouse antibodies for CD45.1 and CD45.2 to separate donor and recipient cells. To detect 
percentage of engrafted LSK cells, we added additional anti-mouse lineage markers (CD11b, 
Gr-1, CD3, CD19 NK1.1 and TER119) together with CD117 (cKit) and Sca-1. Propidium 
iodide (PI) (Invitrogen) was used to exclude dead cells after washing cells.  
All flow cytometry data analysis was done using FlowJo Version 9.3.3 software (TreeStar). 
 
3.5 CELL GROWTH ASSAYS OF AML PATIENT SAMPLES  
Long term culturing of the AML samples was carried out as previously reported (Griessinger, 
Anjos-Afonso et al. 2014). Briefly, mesenchymal MS-5 cells (DSMZ) were irradiated with 
80 Gy, washed, and resuspended at a density of 10,000 cells/100µl of Myelocult media 
H5100 (StemCell Technologies Inc.). To seed feeder cells, 100 µl of cell suspension were 
plated in a collagen I Cellware 96-well plate (Corning), in triplicates for each condition. 2-3 
days after plating feeder cells, 10,000-20,000 AML patient samples were then suspended in 
Myelocult media supplemented with rhIL-6, rhIL-3, rhFl3/Flk-2 ligand, rhTPO, and rhSCF 
and rhG-CSF (Stemcell technology) at a concentration of 20 ng/ml, which were added to 
each well containing a MS-5 monolayer. The plates were kept in a box with water to increase 
the humidity and maintained under normoxic conditions for 3-5 weeks. The effects on cell 
growth (bulk or LICs) were determined by flow cytometric analysis. 
 
3.6 ISOLATION AND CULTURE OF PRIMARY NORMAL CELLS 
To isolate cKit+ or LSK cells, lineage mature blood cells were depleted from BM cells of the 
femur and tibias of C57BL/6 mice by staining cells with purified antibodies against Ter119, 
B220, Gr1, CD3, NK1.1, and CD11b (Biolegend) and Dynabeads (Invitrogen). 
Fluorochrome-conjugated anti-CD117 (cKit) and anti-Sca-1 antibodies were used to sort 
cKit+ or LSK cells with a FACS Aria III (BD). The dead cells were excluded by PI 
(Invitrogen). Normal cKit+/LSK cells were cultured in SFEMII media (Stemcell technology 
Inc.) including; rhFlt3/Flk-2 ligand (Stemcell technology Inc.), rhTPO (Stemcell technology 
Inc.), rhIL-6 (R&D system), rmIL-3 (R&D systems) and rmSCF (R&D systems) at a 
concentration of 20 ng/ml. 
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For enrichment of normal human CD34+cells, Lymphoprep solution (Invitrogen) was used 
for the isolation of the mononuclear cell fraction from the umbilical cord blood cells (UCBs) 
and the CD34+ cells were enriched using a CD34 magnetic activating cell sorting microbead 
kit (Miltenyi Biotec). Enriched CD34+ cells were cultured in SFEMII media supplemented 
with rhIL-6, rhIL-3 (R&D systems), rhFl3/Flk-2 ligand, rhTPO and rhSCF all in a final 
concentration of 20 ng/ml (R&D systems) for 14 days.  
 
3.7 COLONY FORMING UNIT ASSAY  
The colony forming unit (CFU) assay is an in vitro assay used to investigate proliferation and 
differentiation patterns of HSCs and progenitors by assessing their capacity to form colonies 
in a semi-solid medium. The morphology and number of the colonies originating from a 
certain number of input cells provides information about the proliferation and differentiation 
ability of the input cells. Moreover, serial plating of each colony illustrates preliminary 
information about self-renewal capacity of input HSCs.   
To investigate the role of a target gene in proliferation and differentiation of HSPCs, 
knockdown and control groups of normal mouse (cKit+/LSK) or human BM (Lin-
CD34+CD38-) were resuspended in the MethoCult semi-solid media (Stem Cell 
Technologies) in concentrations of 150-300 cells/ml (M3434) for mouse and 200-400 
cells/ml (M4435) for human. After vortexing the mixture vigorously, 1 ml of the cell mixture 
was seeded in a 1cm2 dish with a 16g gauge blunt-end needle. The colonies were counted and 
characterized according their morphology using an inverted microscope at 10–12 days 
(mouse) or 12–14 days (human) after plating. A cluster of more than 50 cells was defined as 
one colony. 
 
3.8 AML MOUSE MODELS AND TRANSPLANTATION STUDIES 
For the in vivo part of studies I, II, III and V, all the mice were kept in a specific pathogen-
free animal facility at Karolinska Institutet, Huddinge, Sweden. The C57BL/6 wild type mice 
and the NOD Scid IL2Rgnull-3-SCF/GM/IL3 (NSG-SGM3) mice were purchased from The 
Jackson Laboratory. All the transplanted mice were monitored daily for symptoms of 
leukemogenesis and disease progression was investigated using complete blood tests.  
The mouse MLL-AF9 AML cells were generated according to a previous study (Somervaille 
and Cleary 2006). cKit+ cells were sorted from the BM of CD45.1+ C57BL/6 mice and they 
were transduced with a retroviral vector expressing the MLL-AF9 fusion oncogene. The 
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transduced cells were kept in in vitro culture and were serially re-plated in semi-solid 
methylcellulose medium containing 20 ng/ml rmSCF, 10 ng/ml rhIL-6, 10 ng/ml rmGM-
CSF, 10 ng/ml rmIL-3 and G418 (0.75 mg/ml) to enrich immortalized cells. Single 
immortalized clones were expanded and transplanted via the tail vein into sub-lethally 
irradiated (600 cGy) CD45.2+ C57BL/6 wild type mice. Once transplanted mice showed 
symptoms of leukemogenesis and disease progression, MLL-AF9 AML cells were harvested 
from the BM of euthanized primary AML mice, sorted by flow cytometry and expanded in 
RPMI medium in the presence of IL3 (10 ng/ml) and 10% FBS. The sorted mouse AML cells 
were used for further in vitro or in vivo experiments.  
For the Kaplan-Meier survival analysis of the AML mouse model, 250,000 mouse MLL-AF9 
AML cells after transduction and selection with puromycin (2 µg/ml) were intravenously 
transplanted into wild type CD45.2 C57BL/6 mice aged 6-8 weeks. After AML onset, the 
mice were euthanized.  
For in vivo experiments with primary human cells including normal hematopoietic cells and 
AML patient samples, we used sub-lethally irradiated (220 cGy) humanized NSG-SGM3 
mice aged 6-10 weeks. The primary cells (normal cells: 25,000-50,000 and AML patient: 
100,000-500,000) samples were transplanted via intra-femoral injection. For detection of 
engrafted cells, the recipient mice were euthanized and the BM cells were collected and 
analyzed by flow cytometry.  
 
3.9 RNA SEQUENCING 
RNA sequencing is a powerful technology to investigate the RNA expression profile of cells. 
Briefly, extracted RNA, either total or poly-A+ mRNA is converted to cDNA fragments and 
adaptors are attached in one or two ends of the fragments. The library fragments can be 
sequenced with high throughput from one end (single-end sequencing) or both ends (pair-
end sequencing). The length of the sequenced reads is around 30-400 bp depending on the 
sequencing technology used. To analyze the reads after sequencing, they are either aligned 
to a reference genome or reference transcript, or they can be assembled de novo without the 
genome sequence. Then mapped data are normalized and bioinformatic analyses such as 
expression level, expression of isoforms and whole transcriptome variation and statistical 
analyses can be performed. 
For RNA sequencing in studies I, II, III, and V, total RNA was extracted from cells using the 
RNeasy Micro Kit (Qiagen) 72 hours after transduction of the cells by sorting or selection 
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with puromycin. TotalScriptTM RNA-seq kit (Epicentre, Madison, WI) was used to prepare 
strand specific pair-end RNA libraries according to the manufacturer’s instructions. Libraries 
were pair-end sequenced using the Illumina platform HiSeq2000 or Nextseq500. RNA-seq 
reads were mapped to the Ensembl Homo sapiens GRCh38 reference genome using the 
STAR aligner. Gene assignment was performed using feature Counts. Normalization and the 
sample group comparison was performed using DESeq2. 
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4 RESULTS AND DISCUSSION 
4.1 RESULTS 
4.1.1 Study I 
In this study, we aimed to identify novel target genes that are selective and essential for 
maintenance of AML. For this purpose, we performed shRNA based screens of the human 
AML cell lines NOMO-1 and a mouse AML cell line. All cell lines were characterized by 
MLL-AF9 translocation. To filter out targets with a strong effect on normal hematopoietic 
cells we used non-transformed mouse Factor-Dependent Continuous Paterson Laboratories 
(FDCP mix) cells as control cells in the screens (Spooncer, Heyworth et al. 1986). The AML 
cells were transduced with lentiviral virus from an RNAi library consisting 27,000 shRNAs 
targeting 5,400 putative disease-associated and drug targets (Cellecta Inc.). The transduced 
cells were harvested at the initial time point (T0) and after ten cells divisions (T10) to 
sequence the PCR-amplified unique barcodes for individual shRNAs. By comparing the ratio 
of each individual barcode at two time points, we identified 1,082 target genes with at least 
a five-fold higher inhibitory effect on mouse AML cell growth compared to FDCP-mix cells. 
Among the 1,082 targets, 34 were common between THP-1 and NOMO-1 cell lines as shown 
by at least a five-fold effect in the screens.  
Among 34 target genes, multiple shRNAs were scored against chromodomain helicase DNA-
binding protein 4 (CHD4) which had a strong growth inhibitory effect on AML cell lines. To 
validate whether CHD4 is required for AML cell growth, we performed an in vitro 
competition assay by mixing shRNA expressing RFP and targeting Chd4 with control 
shRNA tagged with a GFP fluorescent marker. Knockdown of Chd4 with two independent 
shRNAs caused a strong blockade of leukemic cells in THP-1, NOMO-1 and mouse AML 
cells. We then tested the effect of CHD4 knockdown in non-MLL AML cells lines by using 
HL-60, K562 and NB-4 AML cell lines. The result from this in vitro growth assay revealed 
that CHD4 is also crucial for growth of non-MLL AML cells. We used CRISPR/Cas9 
technology to target CHD4 on two human AML cell lines (THP-1, MV4-11) to avoid 
possible off-target effects commonly caused by shRNA, and confirmed that CHD4 
expression is crucial for propagation of AML cells. 
To investigate whether CHD4 plays role in AML progression, we transplanted MLL-AF9 
AML cells into recipient congenic mice. The mice which received Chd4 knockdown AML 
cells survived significantly longer than the control group transplanted with AML cells 
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carrying Sc control shRNA. To check whether CHD4 is important for normal hematopoietic 
cells, we first tested the effect of knockdown on normal mouse HSPCs in a growth assay 
format. The flow cytometric analysis demonstrated a minor difference between cells 
transduced with Chd4 shRNA and control cells. Moreover, a similar result was seen when 
testing CHD4 shRNA in human CD34 positive UCBs. Together, these results indicate that 
CHD4 plays an important role in the growth of leukemic cells in vitro but not in normal 
primary hematopoietic cells.  
Next, we tested knockdown of CHD4 shRNA in primary childhood patient samples ex vivo 
by culturing transduced patient samples either with control shRNA or CHD4 shRNA on MS5 
stromal feeder cells. Flow cytometry analysis demonstrated that the expansion of cells 
transduced with CHD4 shRNA was significantly inhibited compared to control cells, whilst 
the absolute number of LICs were decreased in CHD4 knockdown cells. These results 
suggest that CHD4 inhibition prevents expansion of bulk leukemic cells as well as LICs. 
Interestingly, using a humanized NSG-SGM3 mouse model to transplant childhood patient 
samples transduced with either CHD4 shRNA or Sc control showed that primary childhood 
AML cells transduced with CHD4 shRNA had significantly lower levels of leukemic 
engraftment in recipient mice compared to the Sc control group.  
Cell cycle assay analysis of MLL rearranged AML (THP-1 and MV4-11) and non-MLL 
AML (AML-193 and Kasumi-1) human cell lines revealed that inhibition of CHD4 caused 
an accumulation of cells in G0 phase of cell cycle. Additionally, CHD4 inhibition reduced 
the number of cells in G1 phase but did not significantly affect the number of cells in S and 
G2/M phases compared to control cells. Contrastingly, a minor effect on apoptotic cells was 
observed using CHD4 shRNA.  
Next, to determine the RNA expression pattern induced by CHD4 knockdown, we performed 
RNA sequencing analysis of THP-1 AML cells transduced with CHD4 shRNA. Gene set 
enrichment analysis (GSEA) of RNA-seq data showed that the genes most significantly 
correlated with MYC and E2F targets. Moreover, knocking down of CHD4 induced 
downregulation of MYC and genes involved in G1/S cell cycle such as D1, D2, E1, E2F1 and 
E2F2.  
In this study, we found that the shRNAs targeting CHD4 identified from our screens targeted 
AML cells without a dramatic effect on normal hematopoietic cells, making CHD4 a 
potential therapeutic option for AML. We showed that CHD4 knockdown reduced the 
frequency of bulk AML cells as well as LICs in primary childhood AML samples. 
Additionally, we determined that CHD4 is essential for AML progression and development 
  55 
by testing the effect of knockdown in a congenic AML mouse model and transplanting patient 
samples into NSG-SGM3 mice. These data revealed an important role for CHD4 in childhood 
AML.  
 
4.1.2 Study II 
In this study, our goal was to identify novel TFs essential for AML cell expansion. We 
screened two human cell lines (THP-1 and NOMO-1) and mouse AML cells with a lentiviral 
shRNA library targeting around 5,000 genes within signaling pathways (Cellecta Inc.). The 
transduced cells were harvested at two time points; initial and after 10 cell divisions. Each 
individual shRNA vector contained a unique barcode which was amplified from genomic 
DNA and tracked by NGS. We found 648 target genes which caused at least a five-fold 
reduction in AML cell growth overlapping between THP-1, NOMO-1 and mouse AML cells. 
Among the target genes, 38 of them were TFs and 24 of the 38 were known to be important 
in AML such as MEIS1, HEMS1 and MYC. To avoid strong effects on normal cells, we 
prioritized expression levels of TFs in myeloid leukemia cells and normal hematopoietic cells 
as listed in the BloodSpot data base. GTF2IRD1 is one such TF that was highly expressed in 
leukemic cells.  
To validate GTF2IRD1, we first tested mouse AML cells by performing growth assays using 
AML cells transduced with shRNAs targeting Gtf2ird1, mixed with cells transduced with Sc 
control shRNA. FACS analysis showed Gtf2ird1 knockdown significantly impaired AML 
growth. We found a similar result in five human AML cell lines; THP-1, NOMO-1, HL-60, 
K-562, and NB-4. Then we investigated the importance of Gtf2ird1 in AML development in 
vivo using a congenic AML mouse model. The mice transplanted with Gtf2ird1 knockdown 
AML cells survived longer compared to the recipient mice transplanted with AML cells 
transduced with Sc control shRNA.  
Our next question was if GTF2IRD1 blocks the growth of normal hematopoietic cells. To 
answer this question, we first performed in vitro growth assays on mouse HSPCs. FACS data 
showed no significant difference between cells transduced with Gtf2ird1 shRNA and control 
cells. Furthermore, the CFU assay confirmed Gtf2ird1 is not essential for expansion and 
differentiation of mouse HSPCs in vitro. Transplantation of depleted Gtf2ird1 HSPCs into 
lethally irradiated mice and monitoring the frequency of engraftment demonstrated that 
knockdown of Gtf2ird1 did not strongly affect the reconstitution of HSPCs cells in vivo.  
To explore the effect of GTF2IRD1 inhibition on survival and expansion in normal human 
hematopoietic cells, we performed a growth assay on CD34+ cells enriched from UCBs 
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transduced with GTF2IRD1 shRNA or Sc shRNA. Similar to the results observed with mouse 
HPSCs, we again saw that GTF2IRD1 is not crucial for expansion of human hematopoietic 
cells. Long-term culturing of transduced CD34+ UCBs cells also revealed GTF2IRD1 
inhibition did not influence normal cell growth. Transplantation of CD34+ UCBs into NSG-
SGM3 mice and FACS analysis of engrafted cells after 8 weeks demonstrated no significant 
differences in engraftment between the mice receiving cells with GTF2IRD1 knockdown 
compared to the Sc control group. Altogether, data from mouse and human HSPCs suggest 
that the GTF2IRD1 TF has a selective role in the expansion and development of AML but is 
not important in normal hematopoiesis.  
Additionally, we knocked-out GTF2IRD1 in THP-1 and MV4-11 cells using CRISPR/Cas9 
technology and performed an in vitro competition assay. By comparing cells with gRNA 
targeting GTF2IRD1 to cells transduced with control gRNA, we observed a strong reduction 
in GTF2IRD1 knockout cells which confirmed our result as previously seen in AML cells 
using shRNA.  
To investigate the role of GTF2IRD1 in primary childhood and adult AML patients, we took 
advantage of ex vivo culturing of AML samples on stromal feeder cells. Transduction of 
patient samples with GTF2IRD1 shRNA caused a significant reduction of bulk AML 
(CD45+) cells as well as LICs (CD45+Lin-CD34+Cd38-). Additionally, intrafemoral 
transplantation of transduced cells into NSG-SGM3 humanized mouse cells showed 
GTF2IRD1 knockdown decreased the percentage of engrafted adult and childhood AML 
samples. Altogether, these data confirm that expression of GTF2IRD1 is crucial for the 
survival and maintenance of adult and childhood primary AML cells.  
Cell cycle and apoptosis analysis of mouse AML cells revealed a significant increase in the 
number of cells in the G0 cell cycle phase and reduction in G1, S and G2M phases caused by 
knocking down of Gtf2ird1 compared to control cells. In contrast, the percentage of apoptotic 
cells at the same time point was low, around 2-3%, suggesting that Gtf2ird1 knockdown 
induces an accumulation of cells in the G0 phase of the cell cycle rather than inducing 
apoptosis.  
To find out the role of GTF2IRD1 in gene regulation, we used a heterologous GAL4 reporter 
system (Hansen, Bracken et al. 2008). In this system, the luciferase reporter gene is regulated 
by a thymidine kinase promoter with five GAL4 binding sites, therefore suppressor and 
activation function of a TF fused with GAL4 can be measured by luciferin expression level. 
Tetracycline induction of GTF2IRD1-GAL4 expression suppressed luciferase expression 
levels, suggesting that GTF2IRD1 TF acts as a transcriptional suppressor in AML cells.  
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RNA sequencing of mouse AML cells with Gtf2ird1 knockdown compared to control cells 
revealed that Gtf2ird1 knockdown mRNA profiles were enriched in various cellular 
pathways, including myeloid leucocytes activation, lipid biosynthesis and cell-cell adhesion. 
Furthermore, GSEA showed knockdown of Gtf2ird1 negatively correlated with MYC targets 
data sets (FDR q value=0.0 and NES = -1.7) and KRAS signaling (FDR q value = 0.0, NES 
-1.6).  
 
4.1.3 Study III 
Here we focused on the role of euchromatin histone methyltransferases 1 (EHMT1) in AML. 
EHMT1 and EHMT2 are enzyme homologs which specifically methylate the lysine 9 (K9) 
residue in histone 3 (H3), acting as transcription repressors.  Several studies have shown the 
function of EHMT2 in AML (Lehnertz, Pabst et al. 2014), but the role of EHMT1 in AML 
is not currently clear. 
To first investigate the importance of Ehmt1 in AML, we knock downed Ehmt1 using shRNA 
in mouse MLL-AF9 AML cells and analyzed the growth of AML cells in competition with 
control cells. Monitoring cells via flow cytometry analysis for two weeks showed that 
knockdown of Ehmt1 significantly reduced the frequency of AML cells in vitro. To further 
analyze the role of Ehmt1 in mouse AML cells, we transplanted AML cells into lethally 
irradiated recipient mice with and without knockdown of Ehmt1. Interestingly, transplanted 
cells containing one of the independent shRNAs targeting Ehmt1 prolong the survival of mice 
in comparison to mice transplanted with control cells, which died 18-21 days after 
transplantation. These data suggest that expression of Ehmt1 is necessary for the growth and 
progression of mouse AML cells.  
Next, we studied the importance of EHMT1 in human AML cells lines by transducing them 
with shRNA against EHMT1. Growth assay analysis of five AML cells lines with MLL-AF9 
translocation (THP-1 and NOMO-1) and without MLL-AF9 alteration (HL-60, K-562 and 
NB-4) revealed that the essential role of EHMT1 in mouse AML cell expansion was 
conserved in human AML cells as well. Moreover, suppression of EHMT1 activity with the 
small inhibitor molecule; BIX-01294 in human KL-60 and THP-1 AML cells showed similar 
results in line with EHMT1 shRNA; namely that inhibition of EHMT1 significantly impairs 
the growth of AML cells.  
To confirm the results observed using shRNA, we used CRISPR/Cas9 to knockout EHMT1 
in human AML cell lines. We transduced THP-1 and MV4-11 cell lines with stable 
expression of Cas9-mCherry using a gRNA targeting the EHMT1 gene. Targeting EHMT1 
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with gRNA caused a significant reduction in AML cell growth, confirming our previous 
result regarding the important role of EHMT1 in AML cell growth. 
To find out whether EHMT1 is important for normal hematopoietic cell propagation we tested 
the effect of EHMT1 knockdown on mouse and human HSPCs. In both cases we observed a 
reduction in cell growth, but this reduction in cell number was not as strong as seen in AML 
cells. To further investigate, we performed CFU assays for normal mouse and human HPSCs 
with and without EHMT1 knockdown. The results revealed EHMT1 suppression caused a 
reduction in colony number. Together, these data suggest that AML cell growth is more 
dependent on EHMT1 compared to normal HSPCs.  
Next, to demonstrate the role of EHMT1 in primary AML adult and childhood patient 
samples, we co-cultured transduced cells with either EHMT1 or Sc shRNA with MS5 stromal 
feeder cells (Griessinger, Anjos-Afonso et al. 2014). Flow cytometry analysis to read out the 
frequency of bulk AML cells (CD45+) and LIC (Lin-CD34+CD38-) showed that EHMT1 
knockdown AML cells expanded less compared to control cells. To further investigate the 
role of EHMT1 in the expansion of primary AML cells, we transplanted EHMT1 knockdown 
cells into a NSG-SGM3 mouse model and monitored the engrafted cells by flow cytometry 
up to eight weeks post transplantation. This was in comparison to control mice receiving 
AML cells transduced with Sc shRNA. Engraftment of primary patient samples was 
significantly lower in the group with EHMT1 knockdown. Therefore, these data showed 
EHMT1 also plays an important role in the growth of primary AML samples in in vitro and 
in vivo conditions.  
EHMT2 is another member of the EHMT family, described as a heterodimer to EHMT1 
(Tachibana, Ueda et al. 2005), with important roles in AML previously reported (Lehnertz, 
Pabst et al. 2014). To address the question if EHMT1 and EHMT2 have an overlapping role 
in AML, we designed gRNAs against EHMT1 or EHMT2 with different fluorescent reporter 
markers, enabling us to track them in co-culture conditions and to detect cells carrying both 
gRNAs. Flow cytometry analysis of the competition assay revealed that single knockout of 
EHMT1 or EHMT2 reduced AML growth equally and interestingly, double knockout of 
EHMT1 and EHMT2 did not show an additive effect on AML cell growth.  These data suggest 
that EHMT1 and EHMT2 have a cooperative function in the growth of AML cells.  
To understand the cellular mechanism of EHMT1 and EHMT2 in AML cells, we performed 
cell cycle analysis on mouse MLL-AF9 AML cells with and without knockdown for either 
Ehmt1 or Ehmt2. Interestingly, we observed both Ehmt1 and Ehmt2 knockdown caused a 
significant increase in the proportion of cells in the G0 phase of the cell cycle and 
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simultaneous reduction of cells in S and G2M phases. However, we did not observe a 
significant difference in the number of apoptotic cells, suggesting both EHMT1 and EHMT2 
inhibition induce cell cycle arrest in AML cells in G0. 
To uncover the molecular mechanism of Ehmt1 in the regulation of AML cell growth, we 
RNA sequenced mouse AML cells with Ehmt1 knockdown. Additionally, to detect 
similarities and differences in the RNA expression profiles between Ehmt1 and Ehmt2, we 
performed RNA-seq analysis of Ehmt2 knockdown AML cells. The mRNA profile of Ehmt1 
showed a significant correlation to the Ehmt2 mRNA profile and since both enzymes are 
transcriptional suppressors, they unsurprisingly showed a significant overlap in the 
upregulated genes. Moreover, GO-term analysis of upregulated genes revealed common 
biological processes associated to cytokine signaling, inflammatory response and cell 
differentiation for Ehmt1 and Ehmt2. These RNA-seq data suggest although Ehmt1 and 
Ehmt2 share several biological processes, they may still have further independent roles as 
well.   
 
4.1.4 Study IV 
In this study, we contributed to Nikolas Herold’s study to investigate the effect of SAMHD1 
inhibitor Vpx, in the treatment of patient AML samples with the cytostatic deoxycytidine 
analog cytarabine (ara-C). ara-C is the most common drug for AML treatment and resistance 
to ara-C is the main cause of CR failure and relapse.  
SAMHD1 was identified as a risk factor in cohorts of both childhood and adult AML patients 
who received ara-C treatment. Using simian immunodeficiency virus (SIV) protein Vpx to 
transiently reduce SAMHD1 expression, AML cells demonstrated a markedly increased 
sensitivity to ara-C-induced cytotoxicity. Moreover, disruption of SAMHD1 using 
CRISPR/Cas9 technology showed a similar effect in increasing sensitivity of AML cells to 
ara-C.  
Xenotransplantation of THP-1 cells with or without expression of SAMDH1 into athymic 
nude immunodeficient NMRI nu/nu mice and treatment of the animals with ara-C revealed 
that SAMHD1- tumors responded to the treatment compared to SAMHD1+ tumors.  
Next, we treated adult and childhood AML patient samples under ex vivo conditions with 
virus-like particles (VLPs) either with or without Vpx. Flow cytometric results revealed that 
reduction of SAMHD1 protein levels in patient AML samples increased sensitivity of cells 
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to ara-C. We also showed that Vpx increased the number of apoptotic cells compared to cells 
treated with empty VLP.  
Thus, a low expression level of SAMHD1 is associated with sensitivity of leukemic cell to 
ara-C, suggesting that the targeting of SAMHD1 could be used as a potential therapeutic 
strategy to increase ara-C efficacy in AML patients. 
 
4.1.5 Study V 
Epigenetic regulators play an important role in hematopoiesis. In particular, the self-renewal 
capacity and differentiation abilities of HSCs, acting as the main source of all mature blood 
cells are regulated with epigenetic regulators. In this study, we investigated the role of 
NAP1L3; nucleosome assembly proteins in self-renewing and differentiation of HSCs in vitro 
and in vivo and signaling pathways regulated by NAP1l3 in hematopoiesis. NAP1L3 has been 
reported as one of the 36 transcriptional regulatory genes expressed predominantly in HSCs, 
suggesting a potential role in HSC regulation (Riddell, Gazit et al. 2014). To detect the 
expression level of Nap1l3 in different populations of mouse hematopoietic and progenitor 
cells, we measured the Nap1l3 mRNA level in seven FACS sorted populations; HSC (Lin-
Sca1+cKit+CD105+CD150+), multi-potent progenitors (MPP; LSK+CD105+CD150+), 
lymphoid-primed multipotent progenitors (LMPP; LSK+Flk2high+), common lymphoid 
progenitors (CLP; Lin-IL7Ra+flk2+), pre-granulocyte-macrophage progenitors (pre-GM; 
LSK-CD41-CD150-CD105-), granulocyte-monocyte progenitors (GMP; LSK-CD41-CD150-
FcgR+), and erythrocyte progenitors (pre-CFU E; LSK-CD41-CD105+). Consistent with 
previous studies, qPCR analysis showed that Nap1l3 was exclusively expressed in the HSC 
fraction.  
To explore the importance of Nap1l3 in HSPCs proliferation and differentiation, shRNA-
based knockdown was used to study loss of function of Nap1l3. Knockdown of Nap1l3 in 
FACS sorted mouse Lin-Sca+cKit+ (LSK) cells caused a significant reduction of total CFUs, 
as well as mixed myelo-erythroid CFUs (CFU-GEM) and granulocyte/macrophage CFUs 
(CFU-GM) numbers compared to the LSK cells transduced with negative scramble control 
shRNA. These data suggest that Nap1l3 suppression impairs the proliferation and survival of 
mouse HSPCs in vitro.  
To avoid potential off-target effects associated with shRNAs, we designed gRNAs to target 
Nap1l3 via CRISPR/Cas9 technology. LSK cells were sorted from transgenic mice 
overexpressing Cas9 nuclease and then transduced with gRNA vectors against Nap1l3. 
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Consistent with shRNA-mediated knockdown, knockout of Nap1l3 with CRISPR/Cas9 
caused a significant reduction in the CFU colony number compare to control cells.  
Next, we used exogenous expression vectors to induce expression of Nap1l3 in mouse 
HSPCs. Constitutive overexpression of Nap1l3 caused a significant reduction of the total 
number of CFUs, CFU-GM and CFU-GEM colonies.  
To investigate this further, we transplanted sorted (ckit+) HSPCs transduced with Nap1l3 
shRNA or Sc shRNA into congenic lethally irradiated mice. We then monitored the engrafted 
cells (CD45.1+) in the BM of recipient mice 2, 5, 8 and 16 weeks post-transplantation. Flow 
cytometric analysis revealed knockdown of Nap1l3 caused a significant reduction in 
engraftment. Moreover, by deep analysis of the BM population, we showed a distinct 
reduction in LSK cells mediated by Nap1l3 downregulation.  These data suggest that Nap1l3 
plays an important role in the survival and reconstitution of HSC in both the short- and long-
term in vivo. Furthermore, flow cytometric analysis of mature blood cells showed a decrease 
in the frequency of myeloid cells (CD11b+), granulocytes (Gr-1+) and, contrastingly, an 
increase B cells (CD19+) in Nap1l3 knockdown cells. Altogether, these data show Nap1l3 
may have a role in differentiation regulation of HSCs.  
To dig in to the importance role of NAP1L3 in human HSCs, we transduced enriched HSCs 
(Lin-CD34+CD38-) from UCB cells with two shRNAs against NAP1L3 and Sc control. 
Proliferation analysis of these cells after 48 hours showed that NAP1L3 knockdown impaired 
proliferation and reduced the number of mature cells (Lin+) compared to control cells, 
suggesting that NAP1L3 is required for proliferation and differentiation of HSC in vitro. 
Culturing UCB HSCs with NAP1L3 inhibition on stromal feeder cells (SL/SL and M2-10B4) 
for three weeks showed a significant reduction in CD45+, Lin-CD45+, and UCB HSCs. Also, 
CFU assays on normal human UCB HSCs demonstrated that knockdown of NAP1L3 
significantly reduced the number of colonies as well as burst-forming unit erythroid cells 
(CFU-E/BFU-E), macrophages (CFU-M), granulocytes/macrophages (CFU-G/GM), and 
mixed myelo-erythroid cells (CFU-GEM). To study the effect of NAP1l3 in HSC self-
renewal, we performed a serial plating assay. In doing so, we observed a reduction of colony 
numbers in the first, second and third plating which suggests NALP13 may also be important 
for HSC self-renewal.  
To study the cellular mechanisms controlled by NAP1L3, we performed cell cycle analysis 
and apoptosis assays. Cell cycle analysis of UCB HSCs with NAP1L3 knockdown compared 
to control cells revealed an accumulation of cells in the G0 phase and a reduction of cells in 
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G1. Apoptosis assays of cells showed an increased population in early apoptosis. Altogether, 
knockdown of NAP1L3 induced cell cycle arrest of HSCs in G0 and triggered apoptosis.  
Next, we wanted to see the role of NAP1L3 in vivo, so we transplanted CD34+ HSPC UCBs 
transduced with NAP1L3 or Sc shRNA into humanized NSG-SGM3 mice. Flow cytometric 
analysis of BM cells in recipient mice 8 weeks post-transplantation showed that NAP1L3 
knockdown dramatically reduced engraftment percentage. FACS analysis of human mature 
cells in recipient mice also showed an increase in the percentage of myeloid cells (monocytes, 
dendritic like cells, plasmacytoid dendritic cells) compared to the control group. Therefore, 
NAP1L3 is likely to play an important role during HSC self-renewal and differentiation. 
To uncover the mRNA expression profile induced by NAP1L3 knockdown, we performed 
RNA sequencing of sorted UCB HSCs transduced with NAP1L3 compared to cells 
transduced with control Sc shRNA. GSEA analysis of Biocarta gene set pathways revealed 
that the mRNA profile of cells with NAP1L3 knockdown negatively correlated to cell cycle 
regulation, chromosome function, recombination and replication. We also observed NAP1L3 
knockdown induced upregulation of the HOXA cluster in RNA-seq data, which we confirmed 
by qPCR for all HOXA clusters except HOXA4. Flow cytometry also revealed that protein 
levels of HOXA3 and HOXA5 were upregulated in the presence of NAP1L3 shRNA. In 
conclusion, these data show that downregulation of NAP1L3 in UCB HSCs induces gene 
expression signatures associated with cell cycle progression and HOXA gene expression. 
 
4.2 DISCUSSION 
To design new drugs to eradicate cancer cells, it is very important to selectively target the 
cancer cells without eliminating normal cells. In studies I and II, we found that CHD4 and 
GTF2IRD1 play critical roles in leukemic cell growth in various AML cell lines with different 
mutational backgrounds and in AML development in mouse models. Interestingly, they are 
not pivotal for the normal function of hematopoietic cells.  
In study I, we identified the chromatin remodeler CHD4 from shRNA screens of mouse and 
human AML cell lines and non-transformed FDCP cells. Our results illustrate a novel and 
crucial role of CHD4 in the maintenance and progression of childhood AML by testing the 
patient samples in an ex-vivo co-culture system and a patient-derived xenograft mouse model. 
However, CHD4 knockdown did not show a significant effect on normal mouse and human 
hematopoietic cell growth. Our findings do emphasize a vital role for CHD4 in the expansion 
of primary childhood AML and interestingly in the maintenance of LICs. Using immune 
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phenotyping of surface markers to identify LICs, we found that expression of CHD4 is 
important for them, which is in line with other cancer types (Chudnovsky, Kim et al. 2014, 
Nio, Yamashita et al. 2015). Knockdown of CHD4 revealed an important role of this 
epigenetic factor in the growth of AML by arresting cells in G0. We showed CHD4 inhibition 
causes cell cycle arrest in G0, and our results are supported by other findings recognizing the 
role of CHD4 in the cell cycle (O'Shaughnessy and Hendrich 2013, Polo, Kaidi et al. 2010). 
To illustrate how CHD4 affects the cell cycle, our RNA-seq data revealed a significant 
downregulation of MYC and its target genes under CHD4 knockdown conditions, which 
suggest that the MYC gene may be a downstream target of CHD4 which causes cell arrest in 
G0. To this end, our findings illustrate CHD4 as a potential therapeutic target, which can be 
used to selectively eliminate childhood AML cells and to particularly diminish LICs.  
In study II, we found a novel TF, GTF2IRD1, from large scale shRNA screens and we 
demonstrated that both knockdown and knockout of GTF2IRD1 selectively blocked mouse 
and human AML growth. We found a novel role of TF GTF2IRD1 in maintenance and 
growth of both childhood and adult AML. Although overexpression of GTF2IRD1 was 
reported in AML cells compared to normal hematopoietic cells, our results revealed for the 
first time the functional role of GTF2IRD1 in leukemic cells as well as in LICs growth in 
adult and childhood AML patient samples (Bagger, Sasivarevic et al. 2016). Though more 
investigations are needed to uncover the molecular mechanism of GTF2IRD1 in the growth 
of leukemic cells, our results suggest a selective inhibitory role in AML cell expansion but 
not in normal hematopoietic cells. Additionally, GTF2IRD1 knockdown caused an 
accumulation of AML cells in G0 and downregulation of MYC targets and KRAS signaling. 
Despite the transcriptional repressor function of GTF2IRD1, RNA-seq data from AML cells 
with Gtf2ird1 knockdown revealed a strong downregulation of MYC targets at the mRNA 
level, which might correlate with a secondary side effect of blocking cells in G0 upon 
Gtf2ird1 knockdown rather than a direct regulatory role of MYC target genes. Recently, it 
has been possible to target TFs in new therapies for cancer cells by modifying their 
expression or degradation at the mRNA level, by inhibiting protein-protein interactions, or 
by direct targeting TF and block binding the TF to DNA (Lambert, Jambon et al. 2018). In 
particular, there are several efforts to develop new strategies to target different TFs in AML 
including C/EBPα, PU.1, RUNX1, RUNX2, RUNX3, p53, c-MYC, CREB and STAT3 
(Takei and Kobayashi 2018). Most importantly, we have identified a novel role of GTF2IRD1 
in AML cell growth and maintenance, suggesting a new TF as a promising therapeutic 
candidate to selectively target AML cells. 
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The aim of study III was to investigate the role of histone methyltransferase EHMT1 in AML 
and to establish a connection to its homolog EHMT2. We showed that downregulation of 
EHMT1 had a negative effect on maintenance of AML cells in both in vitro and in vivo. 
Knockdown of EHMT1 reduced the number of bulk and LIC cells in primary AML patient 
samples. Our results suggest that expression of Ehmt1, similar to Ehmt2, is vital for 
proliferation of AML cell lines as well as patient-derived AML samples. Simultaneous 
knockout of EHMT1 and EHMT2 in AML cells did not show an additive effect on cell growth 
compared to single knockout, suggesting that EHMT1 and EHMT2 functionally overlap in 
the regulation of AML growth. Our studies also revealed that both Ehmt1 and Ehmt2 
knockdown arrests cells in G0 of the cell cycle. Furthermore, our RNA-seq data showed 
significant overlap in upregulated genes between Ehmt1 knockdown AML samples and 
Ehmt2 knockdown samples. This is consistent with a previous study showing that Ehmt1 and 
Ehmt2 predominantly form a heterodimer complex in the nucleus and are both cooperatively 
important for H3K9 methylation as an inactivating epigenetic marker (Tachibana, Ueda et al. 
2005). Besides that, our data also revealed several upregulated genes and pathways that are 
not shared between the two groups of knockdown cells, suggesting Ehmt1 and Ehmt2 might 
play independent roles in AML cells in addition to their cooperative role. Since both 
epigenetic enzymes are associated with transcriptional inactivation, downregulated genes 
most likely represent secondary effects of Ehmt1 or Ehmt2 knockdown. Further experiments 
need to be done to clarify the functional relationship between the two epigenetic enzymes 
and promoter regions they bind to together or individually, but it is possible to find 
homodimer complexes of Ehmt1 and Ehmt2 with specific regulatory sites in AML cells. Also, 
more investigations are clearly needed to identify which of the two H3K9me1/2 
methyltransferases shows less pronounced effects on normal hematopoietic cells. Based on 
the results, studies can be performed to design a specific inhibitor that selectively blocks 
either EHMT1 or EHMT2 as therapeutic candidate in AML.  
In study IV, resistance to ara-C and relapse after treatment are the main obstacles to achieve 
long term CR in AML patients. Therefore, finding a prognostic marker to predict 
chemotherapy response will be valuable for AML patients. Here, the data suggested that there 
is a significant correlation between high level expression of SAMHD1 and low sensitivity to 
ara-C in AML patient samples, suggesting the correlation between SAMHD1 expression and 
prediction of ara-C treatment response. The increased sensitivity to ara-C in the absence of 
SAMHD1 could be because of elevated levels of intracellular ara-CTP, which cause 
increased incorporation of ara-C into DNA. However, there is no significant difference in 
SAMHD1 levels between AML patients with CR and patients who did not achieve CR. One 
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explanation could be clonal selection of ara-C resistant sub-clones with higher levels of 
SAMHD1 after therapy that might induce relapse. Moreover, the probable tumor suppressor 
function of SAMHD1 might increase the survival advantage of sub-clones with low 
SAMHD1 expression level over time (Clifford, Louis et al. 2014). Importantly, our results 
suggest that expression of SAMHD1 may be a limiting factor for ara-C therapies and 
evaluation of the level of SAMHD1 could be helpful to avoid toxicity related to increasing 
doses of ara-C. Further efforts are needed to explore strategies to inhibit SAMHD1 in 
combination with ara-C treatment, but these data suggest that leukemic cells can be sensitized 
to ara-C with inhibition of SAMHD1.  
In study V, our investigations recognized a novel role of the histone chaperone NAP1L3 in 
HSCs. Loss of function of the highly expressed NAP1L3 in HSPCs significantly impaired 
survival, proliferation, reconstitution and differentiation of HSCs in vitro and in a 
transplanted mouse model. These data suggest the transcriptional regulatory role of NAP1L3 
on genes that are associated with cell cycle and differentiation processes. While the role of 
Nap1 family proteins in cell cycle regulation and during mitosis has been confirmed, we 
showed for the first time that a specific member of the Nap1 family, NAP1L3, is required for 
regulation of cell cycle in normal hematopoietic cells and its inhibition causes cell arrest in 
G0 (Altman and Kellogg 1997, Grande, Lambea et al. 2008). Our data is in line with previous 
data, which showed that NAP proteins can bind to core histones and physically interact with 
p300 coactivators to regulate target genes including p53 and E2F (Shikama, Chan et al. 
2000). Knockdown of NAP1L3 in human hematopoietic cells caused an abnormal proportion 
of mature cells in a xeno-graft mouse model, which might suggest a regulatory role of 
NAP1L3 in the epigenetic landscape of HSCs during differentiation to produce all lineages 
of mature blood cells. Furthermore, NAP1L3 knockdown decreased the reconstitution and 
self-renewal capacity of HSCs. Although our RNA-seq data from human HSPCs with 
NAP1L3 knockdown did not show significant association with hematopoietic differentiation 
pathways, we showed that five HOXA genes were significantly upregulated upon NAP1L3 
suppression at the mRNA level and two of three investigated at protein level. Since the roles 
of HOXA genes in self-renewing and differentiation of HSCs are well known, the correlation 
between NAP1L3 knockdown and upregulation of HOXA genes may give a clue for the role 
of NAP1L3 in HSC self-renewal and differentiation (Lebert-Ghali, Fournier et al. 2016). 
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5 CONCLUDING REMARKS  
In order to improve quality of life and increase survival of AML patients, it is vital to increase 
our knowledge regarding molecular mechanisms that drive the disease and relapse. 
New advanced techniques including extensive NGS studies of AML genomes from children 
and adults have provided a comprehensive map of the genetic and epigenetic abnormalities, 
as well as the resulting transcriptional changes. Although, all the recurrent mutations in AML 
have at this time been identified, there are still some key questions needing to be answered, 
for instance, which mutations can initiate or contribute to the maintenance of AML? Which 
mutations cause drug resistance and which genes are responsible for relapse?  
Therefore, the next big challenge in this field is to identify and functionally characterize 
genes and pathways with a causative role in the pathogenesis and progression of AML. This 
will provide better understanding of the underlying mechanisms of AML and thereby help in 
the development of novel therapeutic strategies. Functional screening including shRNA 
screening is a promising tool for effective identification of essential genes and pathways in 
AML. In this thesis, we confirmed the reliability of this technique to uncover crucial novel 
genes in leukemic cell growth. Moreover, we established a reliable model system and 
methods including ex-vivo expansion of AML and normal hematopoietic cells and intra-
femoral transplantation of AML patient cells, to investigate the role of novel genes in AML 
disease and revealed the functional role of the selected candidates in leukemic cell growth. 
Hence, our methods might be helpful to shed light on these important questions.  
Furthermore, another major reason for the high mortality rate is that few effective drugs have 
been developed to treat AML. The standard care of treatment, i.e. chemotherapy, has 
remained mainly unimproved over the past 40 years. During the last decade, numerous 
studies have been performed to develop new drugs for the treatment of AML but more than 
90% of them have failed in the clinical phase. The major problem is that these strategies have 
not been efficient to completely eliminate AML patient cells and achieve CR or they cause 
severe side effects on normal cells. Taken together, in AML disease, novel treatment 
strategies are essentially needed to improve the prognosis for these patients. 
One major reason why many new treatments against AML have been failed in clinical trials 
is due to the intra- and inter-tumor heterogeneity of AML. Moreover, LICs, responsible for 
the emergence of the disease and relapse after treatment, are very rare in AML cells derived 
from patients. These are factors that must be considered in any drug discovery research 
program to provide efficient treatments. In contrast, pharmaceutical companies are typically 
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limited to using cell lines with poor predictive capabilities, without testing on relevant normal 
cell based models in pre-clinical trials, which leads to high failure rates in phase I/II clinical 
trials due to low efficacy and high toxicity profiles of new pharmaceutical compounds.  
Since drug development strategies are very time and cost consuming, it might be worth to 
screen and validate the promising compound candidates first on AML patient samples in 
particular LICs and normal hematopoietic cells in early stages of drug development then 
continue with more reliable candidates. Our validation in vitro and in vivo methods may be 
a good resource to select more effective targets and new drugs in AML. In conclusion, for 
future drug development strategies in addition to use advanced techniques, it is important to 
include patient samples as well as relevant normal cells or tissue models to discover new 
efficient treatments with curative potential. 
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